

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2019220368 B2**

(54) Title
Modified viral capsids

(51) International Patent Classification(s)
C07K 14/005 (2006.01) **C12N 15/86** (2006.01)
C12N 15/10 (2006.01)

(21) Application No: **2019220368** (22) Date of Filing: **2019.02.14**

(87) WIPO No: **WO19/158619**

(30) Priority Data

(31) Number	(32) Date	(33) Country
18156932.8	2018.02.15	EP

(43) Publication Date: **2019.08.22**

(44) Accepted Journal Date: **2024.06.13**

(71) Applicant(s)
Tomas Björklund;Marcus Davidsson

(72) Inventor(s)
BJÖRKLUND, Tomas;DAVIDSSON, Marcus

(74) Agent / Attorney
WRAYS PTY LTD, L7 863 Hay St, Perth, WA, 6000, AU

(56) Related Art
WO 2017/197355 A2
WO 2017/066764 A2
WO 2018/022905 A2
WO 2018/022608 A2
WO 2012/145601 A2
WO 2013/029030 A1



(51) International Patent Classification:

C07K 14/005 (2006.01) C12N 15/10 (2006.01)
C12N 15/86 (2006.01)

(21) International Application Number:

PCT/EP2019/053610

(22) International Filing Date:

14 February 2019 (14.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18156932.8 15 February 2018 (15.02.2018) EP

(72) Inventors; and

(71) Applicants: **BJÖRKLUND, Tomas** [SE/SE]; Linnégatan
10D, 224 60 Lund (SE). **DAVIDSSON, Marcus** [SE/SE];
Nils Forsbergsgatan 12, 217 54 Malmö (SE).

(74) Agent: **HØIBERG P/S**; Adelgade 12, 1304 Copenhagen K
(DK).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MODIFIED VIRAL CAPSIDS

FIG.1



(57) Abstract: Methods for identifying polypeptides, e.g. derived from HSV pUL22 protein, which when displayed on a capsid confer a desired property to viral particles comprising such capsids, as well as methods for designing and manufacturing viral vectors and viral particles with improved properties. The identification method is based on a capsid library in which the capsid variant does not form part of the viral genome which contains a barcode and in which the barcode associated with the capsid variant is determined by sequencing before the viral vector is used. Thus, the prevalence of the capsid variant in a biological sample may be determined by sequencing of the barcode alone.



Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

Modified viral capsids

Technical field

The present invention relates to viral vectors and particles and methods and tools for designing and manufacturing the same.

5 Background

Engineering of viral vectors through directed evolution has generated a plethora of potent capsids with improved tropism and function¹⁻⁹. While recent additions of Cre-recombinase restricted selection and deep sequencing for optimization has improved the accuracy and potency of this approach in recent years, it is still restricted by the serial infectivity and chimeras generated during production that requires multiple generations of screening until the real functional capsids surface²⁻⁴. Due to the randomness of the process, a very small fraction of the *de novo* sequences code for valid in frame amino-acid substitutions, and even fewer are assembled correctly. This screening approach is also inherently unreproducible and optimizations have to be conducted post hoc. The resulting capsid variants also provide little insights into the function and what molecular targets are engaged.

A commonly used alternative approach is rational design, where systematic changes are made based on the known properties of the capsid (e.g., the removal of heparan sulfate proteoglycan binding from the AAV2 capsid) or through systematic amino-acid substitutions or display of high affinity nanobodies of the capsid surface¹⁰⁻¹⁴. While functionally more stringent, this approach provides less diversity and has more restricted functional potential.

25 Accordingly, there is a need for methods for designing capsids with improved properties, which are reliable, reproducible and allow great diversity.

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

30

It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.

5 Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise”, “comprising”, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”.

Summary

10 By applying a rationalised, systematic approach on selected proteins known to have or suspected to have a desired property, a library of modified viral vectors encoding modified viral particles can be expressed, where the modified viral particles comprise a modified capsid displaying a fragment of the selected proteins. Using tailored screening, fragments of said proteins which are particularly useful for conferring a desired property to a viral particle can be identified. These can be used to design
15 modified capsids, i.e. capsids displaying one of said identified fragments, with tailored properties. As can be seen in the examples, the methods can be used for example to design viral particles with increased tropism and/or infectivity for a given cell type. The present methods are reliable, reproducible and allow great diversity. The generated capsids can be used for delivering a transgene and find applications not only in
20 methods of treatment and gene therapy, but also in e.g. functional mapping of protein domains and drug screening.

25 According to a first aspect, the present invention provides a viral vector encoding a viral particle for delivery of a transgene to a target cell, said viral vector comprising a modified capsid gene and a transgene to be delivered to the target cell; wherein the modified capsid gene is outside the viral genome and comprises a polynucleotide encoding a polypeptide improving delivery of the transgene and/or targeting to the target cell, and
30 wherein the polypeptide comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 3 to 24, SEQ ID NO: 27 to 35 and SEQ ID NO: 39 to 50, wherein up to three amino acid residues have been deleted, modified or replaced.

According to a second aspect, the present invention provides a modified viral particle for delivery of a transgene to a target cell, said modified particle comprising a modified capsid and a transgene to be delivered to a host cell;

5 wherein the modified capsid improves one or more of: delivery of the transgene to the target cell, targeting to the target cell, infectivity of the viral particle, and/or retrograde transport of the modified viral particle compared to an unmodified viral particle comprising a native capsid gene and the transgene, and the modified capsid gene is outside the viral genome, and

10 wherein the modified capsid comprises a polypeptide selected from the group consisting of SEQ ID NO: 3 to 24, SEQ ID NO: 27 to 35 and to SEQ ID NO: 39 to 50, wherein up to three amino acid residues have been deleted, modified or replaced.

15 According to a third aspect, the present invention provides a method of treatment or prophylaxis of a disease or disorder, said method comprising the step of administering a viral vector or the modified viral particle according to the invention to a subject in need thereof.

20 According to a fourth aspect, the present invention provides a method for identifying a drug having a desired effect, said method comprising the steps of:

- a. Providing a candidate drug;
- b. Administering the candidate drug to a cell;
- c. Providing a modified viral particle according to the invention comprising a modified capsid allowing delivery of the viral particle to the cell of b) and a marker polynucleotide;
- 25 d. Monitoring and comparing expression and/or localisation of the marker polypeptide in the presence and absence of the candidate drug;

thereby determining whether the candidate drug has an effect on the expression of the marker polynucleotide.

30 According to a fifth aspect, the present invention provides a method of delivering a transgene to a target cell, said method comprising:

35 a. providing a modified viral vector or a modified viral particle comprising a modified capsid and encapsulating a transgene, wherein the modified viral vector or the modified viral particle is the viral vector or the viral particle according to the invention; and

- b. injecting said modified viral vector or said modified viral particle into an injection site.

5 According to a sixth aspect, the present invention provides use of a viral vector or a modified viral particle according to the invention in the preparation of a medicament for the treatment or prophylaxis of a disease or disorder.

Herein is provided a method of manufacturing a library of viral vectors, comprising the steps of:

- 10 i) selecting one or more candidate polypeptides from a group of polypeptides having or suspected of having a desired property, and retrieving the sequences of said polypeptides;
- ii) providing a plurality of candidate polynucleotides, each candidate polynucleotide encoding a polypeptide fragment of one of said candidate
15 polypeptides, such that upon transcription and translation each candidate polypeptide is represented by one or more polypeptide fragments of each candidate polypeptide;
- iii) providing a plurality of barcode polynucleotides;
- iv) inserting each candidate polynucleotide together with a barcode
20 polynucleotide into a viral vector, comprising a capsid gene and a viral genome, thereby obtaining a plurality of viral vectors each comprising a single candidate polynucleotide operably linked to a barcode polynucleotide, wherein the candidate polynucleotide is inserted within the capsid gene, the capsid gene is outside the viral genome and the barcode polynucleotide is
25 inserted within the viral genome; wherein the viral vector comprises a marker polynucleotide encoding a detectable marker;
- v) amplifying the plurality of viral vectors obtained in step iv) in an amplification system, wherein each viral vector is present in a plurality of copies in the amplification system; and
- 30 a) retrieving and transferring at least a first part of the plurality of viral vectors from the amplification system of step v) in a reference system, thereby mapping each barcode polynucleotide to one candidate polynucleotide; and

- b) maintaining a second part of the plurality of viral vectors in the amplification system, and optionally transferring all or part of said second part in a production system to obtain a plurality of viral particles.

5 Also provided is a method of designing a viral vector having a desired property, comprising steps i) to v) above and further comprising the steps of:

- vi) retrieving a fraction of viral vectors from the amplification system of step v) b) above, or retrieving at least part of the viral particles from the production system of step v) b) above, and contacting a cell population with said
10 retrieved viral vectors or viral particles;
- vii) monitoring marker expression and selecting the cells wherein marker expression follows a desired pattern;
- viii) identifying the barcode polynucleotides expressed in the cells selected in
15 step vii), thereby identifying the candidate polynucleotides responsible for the desired property and the corresponding candidate polypeptides;
- ix) designing a viral vector comprising a modified capsid gene, wherein the modified capsid gene comprises one of the candidate polynucleotides identified in step viii).

20 Also provided is a method of manufacturing a viral particle having a desired property, said method comprising steps i) to v) above and further comprising the steps of:

- vi) retrieving at least part of the plurality of viral vectors from the amplification system of step v) b) above or retrieving at least part of the plurality of viral particles from the production system of step v) b) above;
- 25 vii) contacting a cell population with the retrieved viral vectors or viral particles obtained in step vi);
- viii) monitoring marker expression and selecting the cells wherein marker expression follows a desired pattern;
- ix) identifying the barcode polynucleotides expressed in the cells identified in
30 step viii), thereby identifying the candidate polynucleotides responsible for the desired property and the corresponding candidate polypeptides;
- x) designing a viral vector comprising a modified capsid gene, wherein the modified capsid gene comprises one of the candidate polynucleotides identified in step ix);

- xi) producing the viral vector of step x) in an amplification system or in a production system, thereby obtaining the viral particle having the desired property.

5 Also provided is a method of delivering a transgene to a target cell, said method comprising:

- a) providing a modified viral vector or a modified viral particle comprising a modified capsid and encapsulating a transgene, wherein the modified viral vector or the modified viral particle is the viral vector or the viral particle defined in step xi) above; and
- 10 b) injecting said modified viral vector or said modified viral particle into an injection site.

Also provided is a library of viral vectors, each viral vector comprising:

- 15 i) a backbone for expressing the viral vector in a host cell;
- ii) a capsid gene and a candidate polynucleotide inserted therein, said candidate polynucleotide encoding a polypeptide fragment of a candidate polypeptide;
- iii) a marker polynucleotide; and
- 20 iv) a barcode polynucleotide;

wherein

the candidate polypeptide is selected from a predefined group comprising one or more polypeptides having or suspected to have a desired property;

25 wherein upon transcription and translation each candidate polypeptide is represented by one or more polypeptide fragments in the library;

the candidate polynucleotide is inserted within the capsid gene of the viral vector so that it can be transcribed and translated to a polypeptide fragment displayed on the capsid, and is operably linked to a barcode polynucleotide inserted within the viral genome,

30 and the marker polynucleotide is comprised within the viral genome and the capsid gene is outside the viral genome.

Also provided is a cell or a plurality of cells comprising the library of viral vectors described herein.

35

Also provided is a viral vector encoding a viral particle for delivery of a transgene to a target cell, said viral vector comprising a modified capsid gene and a transgene to be delivered to the target cell;

wherein

5 the modified capsid gene is outside the viral genome and comprises a polynucleotide encoding a polypeptide improving delivery of the transgene and/or targeting to the target cell.

Also provided are viral particles encoded by the viral vectors described herein.

10

Also provided is a modified viral vector or viral particle for delivery of a transgene to a target cell, said modified viral vector or viral particle comprising a modified capsid and a transgene to be delivered to the target cell;

wherein

15 the modified capsid improves one or more of: delivery of the transgene to the target cell, targeting to the target cell, infectivity of the modified viral vector or modified viral particle, and/or retrograde transport of the modified viral vector or modified viral particle compared to an unmodified viral particle comprising a native capsid gene and the transgene.

20

Also provided is the use of a viral vector, a viral particle, a modified viral vector or a modified viral particle described herein for gene therapy.

25 Also provided is a viral vector, a viral particle, a modified viral vector or a modified viral particle described herein for use in a method of treatment of a disorder, such as a disorder of the nervous system.

30 Also provided is a method of treatment of a disorder, such as a disorder of the nervous system, in a subject in need thereof, said method comprising administration of a viral vector, a viral particle, a modified viral vector or a modified viral particle described herein to the subject.

Also provided is a method for identifying a drug having a desired effect, said method comprising the steps of:

35

- a) Providing a candidate drug;
- b) Administering the candidate drug to a cell;

- c) Providing a modified viral particle comprising a modified capsid allowing delivery of the viral particle to the cell of b) and a marker polynucleotide;
- d) Monitoring and comparing expression and/or localisation of the marker polypeptide in the presence and absence of the candidate drug;
- 5 thereby determining whether the candidate drug has an effect on the expression of the marker polynucleotide.

Also provided is a method for improving tropism of a viral vector or particle toward a target cell, said method comprising steps i) to v) above and further comprising the

10 steps of:

- vi) retrieving at least part of the plurality of viral vectors from the amplification system of step v) b) or retrieving at least part of the plurality of viral particles from the production system of step v) b);
- vii) contacting a cell population comprising target cells with the retrieved viral
- 15 vectors or viral particles obtained in vi) and with a reference viral vector or a reference viral particle comprising a marker;
- viii) monitoring and comparing marker expression in the target cells;
- ix) identifying the candidate polynucleotides in the target cells having increased
- 20 expression of the marker compared to the expression from the reference viral vector or reference viral particle;
- x) designing a viral vector or a viral particle with improved tropism, comprising a modified capsid gene, wherein the modified capsid gene comprises one of the candidate polynucleotides identified in step ix).

25 Also disclosed herein is a method of identifying one or more regions of a polypeptide conferring a desired property to a viral particle comprising a capsid modified by insertion of said polypeptide therein, said method comprising steps i) to v) above and further comprising the steps of:

- vi) retrieving at least part of the plurality of viral vectors from the amplification
- 30 system of step v) b) or retrieving at least part of the plurality of viral particles from the production system of step v) b);
- vii) contacting a cell population comprising target cells with the retrieved viral vectors or viral particles obtained in vi) and with a reference viral vector or a reference viral particle comprising a marker;
- 35 viii) monitoring and comparing marker expression in the target cells;

- ix) identifying the candidate polynucleotides in the target cells having an expression profile of the marker corresponding to the desired property.

Description of the drawings

5 **Figure 1: Generation of highly diverse AAV capsid library for the BRAVE approach**

(A) Pie-chart displaying the 131 proteins with documented affinity to synapses that were identified from the literature. They fall into three major groups, Viral derived (capsid and envelope) proteins, host derived proteins (neurotrophins and disease-related proteins e.g., Tau), Neurotoxins and Lectins. (B) 1. NCBI reference sequences of the 131 proteins were translated into amino acid sequences and computationally digested into 14aa long polypeptides with a 1aa shifting sliding window approach. The 61 314 peptides generated in total consisted of 44 708 unique polypeptides. 2. Three alternative linkers were added to the polypeptides; a single Alanine (called 14aa), a ridged linker with 5 Alanine residues (14aaA5) and a flexible linker with the aa sequence GGGGS (14aaG4S). A last group of aa peptides were similarly generated with a 22aa length and a single Alanine linker (called 22aa). 3. A total of 92 358 aa sequences were then codon optimized for expression in human cells and overhangs added to the ends to allow for directional scar-less Gibson-assembly cloning into the AAV2 Cap gene at the position 588. All resulting oligos with the total length of 170 bp were synthesized in parallel on a CustomArray oligonucleotide array. 4. The resulting pool of oligonucleotides was assembled into a novel AAV production backbone with Cis-acting AAV2 Rep/Cap and ITR-flanking CMV-GFP. A 20bp random molecular barcode (BC) was simultaneously inserted in the 3' UTR of the GFP gene. 5a. Using a uni-directional Cre-recombination approach followed by emPCR-based addition of Illumina sequencing adapters, the entire pool of peptides is then sequenced using Paired-end sequencing linking the random barcodes to the respective peptides in a Look-Up table (LUT). The resulting library contained 3 934 570 unique combinations of peptide and barcode. 5b. In parallel to the LUT generation, the same plasmid library is utilized to generate replication deficient AAV viral vector preps where the peptide is displayed on the capsid surface and the barcode is packaged as part of the AAV genome. Multiple parallel screening experiments are then performed both in vitro and in vivo and after suitable selection (e.g, dissection of the targeted brain region) the mRNA is extracted and the expressed barcodes sequenced. 6. Through the combination of the sequenced barcodes and the LUT, efficacy can be mapped back to

the original 131 proteins and consensus motifs can be determined using the Hammock, hidden Markov-model based clustering approach (7). (C) Two separate productions of AAV libraries were performed with a plasmid concentration of 3 copies per cell (30cpc) or a ten-fold higher concentration (300cpc). To assess which peptides would allow for correct assembly and genome packaging, we DNase treated both batches (to remove non-packaged genomes), lysed the batches and sequenced the barcodes from the preps separately. Due to the very high diversity of the expressed barcodes, the overlap in barcodes contained was very small. However, the absolute majority of all peptides packaged in the 3cpc batch were also recovered in the 300cpc batch. (D) To assess the functional contribution of the inserted peptide we injected the 300cpc library into the forebrain of adult rats and compared the expression pattern to a AAV2-WT vector batch expressing the same transgene (GFP) at the same titer.

Figure 2 Single-generation BRAVE screening in vitro and in vivo

(A-B) In a first proof-of-concept study we decided to utilize the BRAVE technology to screen for the re-introduction of tropism for HEK293T cells *in vitro*. Wild type AAV2 displays very high infectivity attributed to Heparin Sulfate (HS) proteoglycan binding (B). The AAV-MNMnull serotype disrupts this binding through the insertion of an NheI restriction enzyme site at base 587/588 and thereby significantly reduces the HEK293T cell infectivity (B'). In the screening of the 4 million uniquely barcoded capsid variants, we found several regions from the 132 included proteins that conferred a significantly improved infectivity over the parent AAV-MNMnull capsid structure. One peptide from HSV-2 surface protein pUL44 was selected and a first novel capsid was generated named AAV-MNM001. This capsid, when used to package CMV-GFP independently, displayed a significantly increased tropism to the HEK293T cells (B''). In a second experiment, we used the BRAVE technology to improve the infectivity of primary cortical rat neurons *in vitro*. Both AAV2-WT and the AAV-MNMnull vector displays very poor infectivity of primary neurons (D-D') and the AAV-MNM001 displays some improvement (D''). Through the BRAVE screen, we identified a number of peptides clustering over a C-terminal region of the HSV-2 pUL1 protein (C) which when utilized alone in a novel AAV capsid (AAV-MNM002) improved the infectivity of primary neurons in culture dramatically (D'''). (E) Comparison between titers for AAV2 and AAV-MNM001/004/008/009/017/025/026. Titers are shown as genome copies/cell (no of HEK293T at time of transfection). Selected capsids had to be produced at least twice with the same production method to be compared with AAV2. Black lines

represent mean values, the two groups differed significantly using two tailed t-test, $p \leq 0.05$.

Figure 3 Characterization of the AAV-MNM004 capsid for retrograde

5 **transport *in vivo***

(A) In the bioinformatics analysis of the HSV pUL22 protein, a C-terminal region of the protein displayed reproducible transport to all afferent regions; Cortex, Thalamus and Substantia Nigra while not showing the same bias at the injection site in the striatum.

(B-D) HMM clustering of all peptides displaying these properties revealed two
10 overlapping consensus motifs (C). capsid structures respectively. (D) The AAV-MNM004 was compared *in vivo* to the parent AAV2 through the unilateral striatal injection of a scAAV|CMV-GFP vector with each of the two capsid structures. 5 wks post AAV-injection, the animals were sacrificed and sections stained for GFP using immunohistochemistry developed into a brown precipitation staining using the DAB-
15 peroxidase reaction. While the AAV2-Capsid promoted efficient transduction at the site of injection it resulted in very little retrograde transport of the vector. The AAV-MNM004 capsid on the other hand promoted a retrograde transport to all afferent regions as far back as the medial entorhinal cortex.

20 **Figure 4 Utilization of the BRAVE approach to map and understand the function of proteins involved in Alzheimer's disease, both *in vivo* and *in vitro***

(A) Interestingly, the sAAP region shared significant sequence homology with a region of the VP1 protein from the Theiler's murine encephalomyelitis virus (TMEV) with appears to drive its axonal uptake and infectivity. (B-C, E) After deeper

25 characterization, this region consisted of three adjacent conserved motifs with the third motif sharing significant homology with both the VSV-G glycoprotein (well used to pseudotype lenti-viruses to improve neuronal tropism) and the HIV gp120 protein. Two novel capsid structures were generated from this region, AAV-MNM009 and AAV-MNM017. Both novel capsids promoted retrograde transport *in vivo* but AAV-MNM017
30 also displayed additional interesting properties. AAV-MNM017 infected both primary neurons and primary glial cells *in vitro* with very high efficacy. (D-D'') Detection in human primary glial cells. (D): AAV-MNM001 stained with mCherry; (D'): AAV-MNM017 stained with GFP; (D''): co-staining.

Figure 5 Assessment of AAV capsid re-shuffling using BRAVE and generation of capsids infecting DA neurons

(A-B) In a last BRAVE screening experiment we aimed to develop a novel AAV capsid variant with efficient retrograde transport to dopamine neurons of the Substantia Nigra from injections into the Striatal output region. In this screening, we identified two regions of the CAV-2 capsid protein in close proximity. Interestingly, the first peptide shared significant homology with a third region of the same protein (A) while the second peptide (B) shared a peptide motif from the lectin soybean agglutinin (SA) which also efficiently transports from the synapse to the soma of neurons and can therefore be used as a retrograde tracer. (C-C'). Through double fluorescence immunohistochemistry we could then confirm that the majority of these cells were indeed TH-positive and thereby inferred to be DA producing (C''-C'''). Using the same *in vitro* hESC differentiation protocol we then assessed if the *in vitro* neuronal tropism of the *de novo* capsid variants would be maintained also on neurons with human origin. Indeed, all variants (MNM002, 008 and 010) which displayed high tropism on primary rodent neurons also showed much higher tropism than the wild-type AAV-variants.

Figure 6 Functional dissection of the basolateral amygdala and its involvement in the development of anxiety

(A) In a last experiment, we utilized the BRAVE generated AAV-MNM004 capsid variant to answer an outstanding question regarding the functional contribution of the afferents from the basolateral amygdala to the dorsal striatum. This was conducted using a retrograde-induced chemogenetics (DREADD) approach. We injected the AAV-MNM004 vector expressing Cre-recombinase in the dorsal striatum and a Cre-inducible (DIO) chemogenetic (DREADD) vector into the basolateral amygdala (BLA) bilaterally into wild-type rats. (B) After selective induction of activity of the BLA neurons projecting to the dorsal striatum using the DREADD ligand CNO, we found a striking fear and anxiety phenotype here exemplified using the elevated plus maze (EPM) where the animals spent significantly less time on the open arms compared to control animals (where the Cre gene was replaced with GFP). This stands in stark contrast to the believed function of the BLA projections to the ventral striatum promoting positive stimuli. (C) This increases anxiety phenotype was accompanied by significant hypermobility in the open-field arena and a fear phenotype including excessive digging, severe sweating and episodes of freezing (D-E) after the CNO challenges, the animals were sacrificed and the BLA stained for either the HA-tag (identifying the hM3Dq DREADD expression) or mCherry (visualizing the rM3Ds DREADD) using

immunohistochemistry developed into a brown precipitation staining using the DAB-peroxidase reaction.

Figure 7 AAV production approaches

5 (A) 3-plasmid approach. The AAV genome is divided into two plasmids, a Transfer plasmid and a Packaging plasmid. The required genes from the Adenovirus (Ad) are then supplied in *trans* using a third, helper plasmid. The Transfer plasmid contains the genetic sequence to be packaged into the produced virions. This sequence is flanked by inverted terminal repeats (ITR) from AAV to be replicated and inserted into the
10 capsid. This plasmid contains a gene of interest (GOI) driven by a Promoter and has a 3'untranslated region (3'UTR) and a poly-adenylation sequence (pA). The packaging plasmid contains the remaining parts of the wild-type AAV genome i.e., the Rep and the Cap genes usually driven by a strong promoter to increase titers. As these genes are no longer flanked by ITR sequences they are not packaged in the final AAV virions.
15 The Helper plasmid contains the Ad E4, E2a and VA genes which, together with the Ad genes E1a and E1b, which may already expressed in the production cell line, allow for the AAV production. (B) 2-plasmid approach. The transfer plasmid is as in (A) but the Helper and packaging plasmids were merged into one larger plasmid. This retains the ability to produce replication deficient AAV-viruses using fewer plasmids. (C)
20 Alternative 2-plasmid approach. The helper plasmid is as in (A) but the Transfer and Packaging plasmids are merged into one functional plasmid, providing both the Rep/Cap functionality and the ITR-flanked genome to be inserted into the AAV virion while the AAV vector is still replication deficient. This allows for the utilization of a much smaller amount of Transfer/packaging plasmid while maintaining titers as the Helper
25 plasmid is rate limiting. It also ensures a perfect matching between the Cap gene and the GOI packaged inside.

Figure 8 Cre-recombinase modulated readout

30 A two-factor selection regime may be used for *in vivo* selection of novel AAV capsid variants, which is exemplified here. The first factor is the site of delivery, e.g., systemic, intraventricular injection or intraparenchymal injection into a specific neuronal nucleus of choice. The second factor is a recombinase such as Cre recombinase or a DNA or RNA modifying protein such as Cas9, Cas13 or CPF1. This protein can be supplied either through the generation of transgenic animals or via viral vector. As a viral vector
35 this can be delivered in a specific secondary brain nucleus to label only select afferents for capsid screening. The approach here shows a novel strategy that allows for on-

target and off-target mapping based on barcodes sequenced from mRNA. The value of mRNA sequencing is that only successful infectivity results in mRNA formation and thus false-positives (non-infective particles retained in tissue) are excluded. (1) The delivered viral vector library contains a genome with the following key components. i) A molecular barcode (BC) which enables identification of the capsid structure based on an *in vitro* look-up table. ii) A unique sequencing primer binding site (SPBS) which enables enrichment and amplification of the library-derived mRNA for sequencing. iii) A synthetic polyadenylation site (spA) which terminates transcription only in the forward direction. iv) A Marker gene for on-target selection in the case of a low-abundance target. v) Two pairs of non-cross-compatible loxP recombination sites which provide an irreversible re-orientation in the presence of Cre-recombinase. vi) A unique 5' untranslated region (5'UTR) which enables selective amplification of the barcodes from mRNA for sequencing in off-target cells. vii) A 3'UTR sequence for the same type of amplification in the on-target cells. (2) In the absence of Cre-recombinase, i.e., after off-target infectivity, the barcodes can be recovered and sequenced from mRNA using primers targeting the 5'UTR and the SPBS sites. This enables mapping of capsid variants with broad, non-selective infectivity. (3) When a virion infects a cell of interest, i.e., a Cre-expressing cell, recombination occurs between the two pairs of loxP sites. This results in a reversal of the orientation of the Marker gene, barcode and the SPBS sequence. (4) In the on-target cells the expressed mRNA allows for the translation of the Marker gene into protein but retains the SPBS and barcode as part of the mRNA 3'UTR thanks to the spA sequence not being active in the reverse orientation. From this mRNA, the barcodes can be selectively enriched and amplified using primers targeting the SPBS and the 3'UTR sequence.

25

Detailed description of the invention

The present disclosure provides a rationalised, systematic approach to design and manufacture a library of modified viral vectors encoding modified viral particles, where the modified viral particles comprise a modified capsid displaying a polypeptide fragment of selected proteins. Using tailored screening, fragments of said proteins which are useful for conferring a desired property to a viral particle can be identified. These can be used to design modified capsids, i.e. capsids displaying one of said identified fragments, with tailored properties. As can be seen in the examples, the methods can be used for example to design viral particles with increased tropism for a given cell type.

35

Definitions

Expression: The term 'expression' of a nucleic acid sequence or polypeptide encoding a polypeptide refers to the transcription of that nucleic acid or polypeptide sequence as mRNA and/or transcription and translation of that nucleic acid sequence or polypeptide resulting in production of the protein encoded by the polynucleotide.

Gene therapy: The term 'gene therapy' used herein refers to the insertion of genes into an individual's cells and tissues to treat a disease.

Insertion: The term "insertion" is herein used to refer to polynucleotides or polypeptides which are inserted in a capsid gene or protein, respectively. A polynucleotide inserted in a capsid gene is inserted at a given position, "in addition" to the capsid gene; no polynucleotide fragment of the parent capsid gene is replaced by the polynucleotide, and the length of the capsid gene in which the polynucleotide is inserted is thus equal to the length of the parent capsid gene plus the length of the inserted polynucleotide. Likewise, the length of a capsid protein displaying a given polypeptide is equal to the length of the parent capsid protein plus the length of the displayed polypeptide.

Modified: The term is herein used in reference to a viral particle, a viral vector, a capsid gene or a capsid. A modified capsid is a capsid which displays a polypeptide as identified by the screening methods described herein. The capsid may thus have properties which have been altered by the insertion of said polypeptide. By extension, a modified capsid gene refers to a capsid gene in which a polynucleotide has been inserted, encoding for a polypeptide which when displayed on the capsid potentially alters its properties. Likewise, a viral vector is modified if compared to the viral vector from which it is derived it comprises an additional polynucleotide sequence encoding for a polypeptide which when displayed on the viral capsid may alter the capsid properties. A viral particle is modified if it comprises a modified capsid.

Operably linked: The term 'operably linked' as used herein when referring to two polynucleotides indicates that identification of one of the two polynucleotides enables identification of the other of the two polynucleotides. The two polynucleotides that are operably linked may be physically part of the same nucleic acid molecule, or they may be on different nucleic acid molecules, i.e. they may be operably linked *in trans*.

35

Promoter: The term 'promoter' used herein refers to a region of DNA that facilitates the transcription of a particular gene. Promoters are typically located near the genes they regulate, on the same strand and upstream.

5 Transgene: The term herein designates a polynucleotide, which it is desirable to introduce in a host cell or a target cell, and which is not naturally or natively expressed in said cell.

Viral genome: The term herein refers to the polynucleotide regions (DNA or RNA) which are flanked by terminal repeats (TR) and consequently packaged within a virion. For DNA viruses, the terminal repeats are inverted and termed inverted terminal repeats (ITR). Retroviruses and lentoviruses typically have long terminal repeats (LTR). Accordingly, a gene such as a capsid gene, which is outside the viral genome, may be on the same polynucleotide molecule as the viral genome, but is not flanked by TR
10 sequences and is thus not packaged within the virions.
15

Library of viral vectors or particles

The present inventors have developed a method for manufacturing a library of viral vectors or viral particles, from which viral vectors or viral particles having a desired
20 property can be selected. The method is based on the selection of a number of candidate polypeptides known to have or suspected of having a desired property, and identification of fragments thereof which, when displayed on a viral particle, confer the desired property to the thus modified viral particle.

25 Using the present methods, it is thus possible to design viral vectors encoding viral particles having a desired property, for example viral particles with improved tropism, or viral particles selectively targeting a specific type of cells. Such viral particles may be useful for a number of applications, e.g. gene therapy, particularly gene transfer to the central nervous system (CNS) and drug screening.

30 Accordingly, herein is provided a method of manufacturing a library of viral vectors comprising the steps of:

i) selecting one or more candidate polypeptides from a group of polypeptides having or suspected of having a desired property, and retrieving the
35 sequences of said polypeptides;

- 5
- ii) providing a plurality of candidate polynucleotides, each candidate polynucleotide encoding a polypeptide fragment of one of said candidate polypeptides, such that upon transcription and translation each candidate polypeptide is represented by one or more polypeptide fragments of each candidate polypeptide;
- 10
- iii) providing a plurality of barcode polynucleotides;
- iv) inserting each candidate polynucleotide together with a barcode polynucleotide into a viral vector, comprising a capsid gene and a viral genome, thereby obtaining a plurality of viral vectors each comprising a single candidate polynucleotide operably linked to a barcode polynucleotide, wherein the candidate polynucleotide is inserted within the capsid gene, the capsid gene is outside the viral genome and the barcode polynucleotide is inserted within the viral genome; wherein the viral vector comprises a marker polynucleotide encoding a detectable marker;
- 15
- v) amplifying the plurality of viral vectors obtained in step iv) in an amplification system, wherein each viral vector is present in a plurality of copies in the amplification system; and
- a) retrieving and transferring at least a first part of the plurality of viral vectors from the amplification system of step v) in a reference system, thereby mapping each barcode polynucleotide to one candidate polynucleotide; and
- 20
- b) maintaining a second part of the plurality of viral vectors in the amplification system, and optionally transferring all or part of said second part in a production system to obtain a plurality of viral particles.

25 Also provided is a library of viral vectors, each viral vector comprising:

- i) a backbone for expressing the viral vector in a host cell;
- ii) a capsid gene and a candidate polynucleotide inserted therein, said candidate polynucleotide encoding a polypeptide fragment of a candidate polypeptide;
- 30
- iii) a marker polynucleotide; and
- iv) a barcode polynucleotide;

wherein

the candidate polypeptide is selected from a predefined group comprising one or more polypeptides having or suspected to have a desired property;

35 wherein upon transcription and translation each candidate polypeptide is represented by one or more polypeptide fragments in the library;

the candidate polynucleotide is inserted within the capsid gene of the viral vector so that it can be transcribed and translated to a polypeptide fragment displayed on the capsid, and is operably linked to a barcode polynucleotide inserted within the viral genome,

5 and the marker polynucleotide is comprised within the viral genome and the capsid gene is outside the viral genome.

Candidate polypeptides and polynucleotides

10 In a first step, one or more candidate polypeptides are selected and their sequences are retrieved. The candidate polypeptides are polypeptides which are expected or suspected to confer a desired property to a viral particle when displayed on the capsid surface. The one or more candidate polypeptides may be one polypeptide, for instance if one desires to map the functional domains of the polypeptide with the methods described herein below, or it may be several polypeptides, as detailed below.

15

The candidate polypeptides may thus be known to be or suspected of being responsible for a given property. For example, in order to select polypeptides which potentially confer increased tropism toward a given type of cells when displayed on a capsid, a first polypeptide known to be transported to said type of cells may be
20 selected. The remaining candidate polypeptides may be identified by running a blast query to identify other polypeptides, potentially from other entities, sharing motifs with the first polypeptide. The term "entity" should here be construed in the broadest sense and encompasses living organisms as well as viruses, prions and the like. Alternatively, all polypeptides from a given entity known to have or suspected of having said desired
25 property at least in some conditions may be selected. The sequences of the selected candidate polypeptides are retrieved, by methods known to the skilled person. In the event that the sequences of the candidate polypeptides are not known, methods are available to the skilled person to determine said sequences.

30

Alternatively, the candidate polypeptides may originate from a peptide library, such as a synthetic library, for example a random peptide library. In some embodiments, the candidate polypeptides are not derived from the viral vector on which they are to be displayed. In some embodiments, the candidate polypeptides are derived from a mutant library; in a particular embodiment, the mutant library does not comprise

mutants derived from a polypeptide which is native to the viral vector on which the polypeptides are to be displayed.

5 In a next step, a plurality of candidate polynucleotides is provided. The candidate polynucleotides encode fragments of the candidate polypeptides. The plurality of candidate polynucleotides may be ordered from a commercial provider, or designed and synthesised by the user. For instance, the sequence of the candidate polynucleotides may be drawn on paper or in silico, and order from a commercial provider, or synthesised by methods known in the art, for example on an array, as
10 shown in example 1.

In some embodiments, the sequences of the candidate polynucleotides are codon-optimised for transcription in a given host cell, as is known in the art.

15 Each candidate polypeptide is represented by one or more polypeptide fragments each encoded by a candidate polynucleotide. In some embodiments, each candidate polypeptide is represented by at least two overlapping polypeptide fragments encoded by at least two polynucleotides, such as at least three overlapping polypeptide fragments encoded by at least three polynucleotides. It follows that the polynucleotides
20 encoding the polypeptide fragments also overlap. As will be obvious to the person of skill in the art, the number of polypeptide fragments for different candidate polypeptides may be different. This is simply because it may in some cases be more convenient to design candidate polynucleotides that all have the same length, the number of candidate polynucleotides encoding overlapping polypeptide fragments of the same
25 polypeptide thus being a function of the length of the corresponding candidate polypeptide. In other embodiments, the number of polypeptide fragments per candidate polypeptide may be the same for all candidate polypeptides, but their lengths may be different.

30 In some embodiments, it may be desirable to span all possible polypeptide fragments of a given length for a given candidate polypeptide. In such embodiments, the candidate polynucleotides are designed in such a way that all the candidate polynucleotides encoding polypeptide fragments of a same candidate polypeptide overlap over at least some of their length, such as over at least one codon. For
35 maximal diversity to be reached, candidate polynucleotides encoding polypeptide fragments of a same candidate polypeptide preferably overlap but for one codon, so

that all polypeptide fragments of a same candidate polypeptide overlap but for one amino acid residue. Such an approach is illustrated in the examples.

5 In other embodiments, the candidate polynucleotides encoding polypeptide fragments of a same candidate polypeptide overlap but for two codons, three codons, four codons, five codons, or more. Preferably, candidate polynucleotides encoding polypeptide fragments of a same candidate polypeptide overlap over at least one codon, such as at least two codons, such as at least three codons.

10 In some embodiments, the polypeptide fragment has a length of between 5 and 36 amino acid residues, such as between 5 and 30 amino acid residues. In one embodiment, the polypeptide fragment has a length of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 residues.

15 In some embodiments, the polypeptide fragments all have the same length. In other embodiments, the polypeptide fragments have different lengths.

20 The polynucleotides encoding the polypeptide fragments of candidate polypeptides are to be inserted in the viral vector encoding the viral particle on which the polypeptide fragment is to be displayed; preferably the candidate polynucleotide is inserted within the capsid gene. Preferably, the capsid gene is outside the viral genome, i.e. it is not flanked by TR or ITR sequences. The resulting modified capsids thus each display a polypeptide fragment. Capsids have been studied thoroughly for a long time and the skilled person will have no difficulty in identifying suitable positions for inserting a
25 polypeptide fragment to be displayed on the capsid.

30 As the skilled person is aware of, in embodiments where the viral particle is an AAV, the insertion site is preferably outside the lipase domain of VP1. It should also preferably be outside the assembly-activating protein (AAP). The insertion site may be at the N-terminus of VP2. It may also be at the vertices of the assembled capsid, e.g. centered around amino acid residue 587 of the Cap gene of AAV2 or around amino acid residue 588 of the AAV9 cap gene.

35 In preferred embodiments, the capsid displaying the candidate polypeptides has not otherwise been modified, i.e. its amino acid sequence is otherwise identical or

essentially identical to the native or wild-type capsid. Accordingly, the length of the capsid protein displaying the polypeptide is in some embodiments always greater than the length of the native, unmodified capsid protein. In such embodiments, no polypeptide fragment of the native capsid is replaced by the candidate polypeptide, and all residues of the native capsid are also present in the modified capsid displaying the candidate polypeptide.

In embodiments where the viral vector is AAV2, the polynucleotides encoding the polypeptide fragments of candidate polypeptides may be for example designed so that the resulting polypeptide fragment is inserted between residues N587 and R588 of the VP1 capsid protein.

Barcode polynucleotides

Once the number of polypeptide fragments, and hence of candidate polynucleotides, has been determined, a plurality of barcode polynucleotides is provided. The barcode polynucleotides are unique, as will be detailed below. It will be recognised by the skilled person that the barcode polynucleotides preferably have a sequence which is not found in any of the candidate polynucleotides. The barcode polynucleotides should also preferably not be naturally present in the cell which is to be used as a production system, in order to avoid background noise in later steps. Additionally, the barcode polynucleotides should also not be naturally present in the host cells in which the library is to be expressed and screened in the methods of the present disclosure. The minimal length of the unique barcode polynucleotides will depend on the number of candidate polynucleotides, as will be evident to the skilled person. Each candidate polynucleotide is operably linked to a single barcode polynucleotide. Thus, the number of barcode polynucleotides is at least equal to the number of candidate polynucleotides or fragments. By "operably linked" is meant that each single candidate polynucleotide fragment is directly or indirectly connected to a single barcode polynucleotide, thereby also providing a link between each candidate polypeptide fragment and the corresponding unique barcode polynucleotide. Thus, the identification of a barcode allows identification of the corresponding polynucleotide fragment or polypeptide fragment. No barcode polynucleotide fragment can be linked to two different candidate polynucleotides (and hence indirectly two different candidate polypeptide fragments).

Methods to synthesise barcode polynucleotides are known in the art. These can also be ordered from a commercial provider.

Once unique pairs of candidate polynucleotides and barcode polynucleotides have been obtained, each pair is inserted in a viral vector to obtain a plurality of viral vectors each comprising a single candidate polynucleotide operably linked to a barcode
5 polynucleotide. The viral vector comprises at least a capsid gene, which may be provided outside the viral genome, or *in trans*. By “viral genome” is meant the part of the viral DNA which is packaged in viral particles which is located within the inverted terminal repeats (ITRs) delimiting the end of the DNA molecule, or the part of the viral RNA which is packaged in viral particles, located within terminal repeats (TR) such as
10 long terminal repeats (LTR) delimiting the end of the RNA molecule. The viral vector may also comprise a *rep* gene, which may also be provided *in trans*. The capsid gene (*cap*) and/or the *rep* gene may thus be provided in a packaging plasmid or as part of a helper plasmid (figure 7).

15 The pairs of candidate polynucleotides and barcode polynucleotides may be inserted in the viral vector simultaneously or sequentially. As explained above, since the method aims at screening modified capsids displaying polypeptide fragments in order to identify polypeptides conferring a desired property to a viral particle, the candidate polynucleotide is preferably inserted within the capsid gene, which is outside the viral
20 genome. By contrast, the barcode polynucleotide is preferably inserted within the viral genome, i.e. between the terminal repeats, such as long terminal repeats or inverted terminal repeats. Without being bound by theory, this design avoids clonal enrichments and removes the bias introduced by PCR, which may be sequence-dependent. By sequencing the barcodes from RNA, the potential PCR bias is reduced and
25 independent from the sequence of the modified capsid. Also, copy count per barcode does not influence the readout.

The barcode polynucleotide may be under the control of a promoter, as described below for the marker polynucleotides. Preferably, the barcode polynucleotide is
30 introduced in the viral genome so that it can be transcribed, and optionally translated, when the viral particle has infected a cell.

It will be clear from the above that even though the barcode polynucleotide and the candidate polynucleotide are operably linked, they need not be contiguous on a same
35 nucleic acid molecule.

Marker polynucleotide

The viral vector comprises a marker polynucleotide which encodes a detectable marker. The detectable marker enables monitoring of the expression pattern of the viral particles.

5

The marker polynucleotide may be any polynucleotide which upon transcription yields a stable mRNA molecule which is not naturally produced in the host cells in which the library of viral vectors is to be introduced in order to identify the candidate polypeptides responsible for a desired property, as detailed below. In some embodiments, the marker polynucleotide may encode a detectable marker, such as a fluorescent marker, which can be visualised or otherwise detected upon expression. The marker polynucleotide may also in some embodiments be the barcode itself. This can be relevant, for example when it is desirable to identify viral vectors which can infect cells which express a recombinase system, by the methods described herein below. The recombinase system may be a Cre recombinase combined with loxP sites, a CRISPR/Cas system such as CRISPR/Cas9, CRISPR/Cas13 or CRISPR/Cpf1.

10

This is illustrated, by way of example, on Fig. 8, where the recombinase is a Cre recombinase. A viral vector (here an AAV vector) comprising a barcode (BC) sequence between two pairs of loxP sites in opposite directions is shown. The region comprised within the loxP sites also comprises a binding site for a universal sequencing primer (SPBS). As is known in the art, if such a vector is transcribed in a cell expressing Cre recombinase, recombination between loxP sites will result in inversion of the sequence comprised therebetween. By contrast, in the absence of Cre expression, there will be no recombination and no inversion. The two events can be discriminated at the mRNA level by sequencing with a primer binding to SPBS and a primer binding to the 5'UTR or a primer binding to the 3'UTR. By sequencing the barcodes with primers binding to the 5'UTR and to SPBS, capsid variants having broad, non-selective infectivity can be mapped.

15

20

A polyadenylation site may be inserted downstream of the marker gene, as exemplified in figure 8, in such a way that transcription is only terminated if the polyadenylation site is in the forward transcription, i.e. transcription is only terminated if there is no recombination, in the absence of Cre recombinase. Transcripts issued from such cells will thus lack a barcode. By contrast, if Cre is expressed, transcription is not terminated, and the transcripts include a barcode. Sequencing of the transcripts thus

25

30

35

allows discriminating between transcripts originating from cells expressing Cre recombinase and transcripts originating from cells lacking Cre recombinase expression.

5 The Cre recombinase may be provided in the cell via a vehicle such as a plasmid. It may also be comprised within the viral vector itself. Only the cells actually infected with the corresponding viral particle will thus express the Cre recombinase. The Cre recombinase may also be expressed by the host itself, for example when screening the library in a transgenic animal.

10

It is to be understood that the box marked "marker gene" on the figure is optional – as explained above, the barcode itself may serve the function of marker. In embodiments where a marker is present which is different from the barcode, it is to be noted that expression of the marker may require recombination to happen, as exemplified on the figure, so that the marker is downstream of the promoter and in the right direction.

15

In some embodiments, the marker polynucleotide encodes a marker polypeptide. The marker polypeptide may be selected from the group consisting of: a fluorescent protein, a bioluminescent protein, an antibiotic resistance gene, a cytotoxic gene, a surface
20 receptor, β -galactosidase, the TVA receptor (the cellular receptor for subgroup A avian leukosis virus), pro-mitotic/oncogenes, trans-activators, transcription factors and Cas proteins. Numerous examples of suitable marker polypeptides or polynucleotides are known to the skilled person.

25

In some embodiments, the barcode polynucleotide is different from the marker polynucleotide and is located at the 3' untranslated region (3'-UTR) of the marker polynucleotide. The barcode polynucleotide may, even if not used as main marker, still serve the function of additional marker polynucleotide.

30

In some embodiments, the marker polynucleotide is codon-optimised based on the codon preferences of the target cells in which the library of viral vectors is to be screened.

35

The marker polynucleotide may be under the control of a promoter. Accordingly, in some embodiments, the marker polynucleotide further comprises a promoter sequence. The promoter may be a constitutive promoter or an inducible promoter.

When the barcode polynucleotide is not the marker polynucleotide, the barcode polynucleotide may be under the control of the same promoter as the marker polynucleotide.

5 The marker polynucleotide may be oriented in such a way relative to the promoter that transcription is only possible if the cell expresses a recombinase system, as explained above. The marker polynucleotide may comprise a polyadenylation site, which may be oriented in such a way that it terminates transcription only in one direction, as explained above for figure 8.

10

The choice of the promoter may be directed by the nature of the desired property which one wishes to screen the library for. Examples of promoters are: phosphoglycerate kinase (PGK), chicken beta actin (CBA), cytomegalovirus (CMV) early enhancer/chicken β actin (CAG), hybrid CBA (CBh), neuron-specific enolase (NSE),
15 tyrosine hydroxylase (TH), tryptophan hydroxylase (TPH), platelet-derived growth factor (PDGF), aldehyde dehydrogenase 1 family member L1 (ALDH1L1), synapsin-1, cytomegalovirus (CMV), histone 1 (H1), U6 spliceosomal RNA (U6), calmodulin-dependent protein kinase II (CamKII), elongation factor 1-alpha (Ef1a), forkhead box J1 (FoxJ1), or glial fibrillary acidic protein (GFAP) promoters. The CMV, H1, U6, CamKII,
20 Ef1a, FoxJ1 and GFAP promoters are known to be suitable for expression of polynucleotides in the central nervous system.

Viral vectors

Viral vectors which are suitable for modification by the methods disclosed herein
25 comprise vectors derived from an adeno-associated viral (AAV) virus, a retrovirus, a lentivirus, an adeno-virus, a herpes simplex virus, a bocavirus and a rabies virus. Preferably, the viral vector is derived from a virus which is suited for delivering a transgene to a target cell. The transgene may be a gene used in gene therapy methods, or it may be a gene encoding a product of interest which it may be desirable
30 to produce in the target cell.

Amplification system

Once the plurality of viral vectors has been constructed, it is introduced in an amplification system. This allows multiple copies of each viral vector to be produced.
35 The amplification system is any cell population suitable for the purpose, as is known to

the person of skill in the art. Preferably, the amplification system is a prokaryotic cell population, e.g. a bacterial system, e.g. *Escherichia coli*.

5 The amplification system can be used to maintain the library, i.e. it can be used to preserve a part of the library containing at least one of each of the viral vectors of the library, in such conditions that the viral vectors can be retrieved from the amplification system. For instance, cells of the amplification system containing the library can be frozen and stored at -80°C. Aliquots can be taken from the stored amplification system to further amplify the library, and optionally to retrieve the viral vectors by methods
10 known in the art.

Reference system

In order to determine how each candidate polynucleotide (and hence each polypeptide fragment) is operably linked to a barcode polynucleotide, a first part of the plurality of
15 viral vectors is retrieved from the amplification system above and transferred to a reference system. The reference system is a cell population from which the viral vectors can be further analysed. Preferably, the reference system is a bacterial cell population. The reference system is used to map the correspondence between candidate polynucleotide and barcode polynucleotide. This mapping step can be
20 performed in several ways, e.g. retrieving viral vectors from the reference system and subsequently sequencing a region of each viral vector, where the sequenced region preferably comprises at least the barcode polynucleotide and the candidate polynucleotide.

25 In some embodiments, a look-up table is generated, listing which barcode polynucleotide is linked to which candidate polynucleotide, and hence to which polypeptide fragment. An example of how to do this is illustrated in example 1 and figure 1B. After Cre-recombination followed by emPCR-based addition of Illumina sequencing adapters, the entire pool of candidate polynucleotides operably linked to
30 random barcode polynucleotides was sequenced by paired-end sequencing, thereby obtaining a look-up table linking each polypeptide fragment to a unique barcode polynucleotide. Other methods to generate a look-up table will be evident to the skilled person.

Thus, the parallel use of an amplification system and a reference system allows the generation of viral vector preps simultaneously with the mapping of the correspondence between each barcode and each polypeptide fragment.

5 Production system

In order to manufacture a library of viral particles from the library of viral vectors, a production system may be needed. The production system comprises a cell, and may further comprise plasmids or vectors comprising the elements necessary for the viral vectors to replicate and/or produce viral particles if these elements are not comprised within the viral vectors themselves, as is known in the art. Part of the plurality of viral vectors can thus be retrieved from the amplification system described above, so that said part comprises at least one of each of the viral vectors of the library, and can subsequently be transferred into a production system to obtain a plurality of viral particles.

15

The production system may comprise or consist of a mammalian cell, for example a human cell, an insect cell such as an SF9 cell, or a yeast cell such as a *Saccharomyces cerevisiae* cell. In some embodiments, the mammalian cell is a Hela cell, a primary neuron, an induced neuron, a fibroblast, an embryonic stem cell, an induced pluripotent stem cell, or an embryonic cell, such as an embryonic kidney cell, for example HEK293 cells.

20

The production system may further comprise vectors, e.g. plasmids, required for producing the viral particles in the cell. Figure 7 shows several such plasmid systems exemplified for production of a DNA virus. Typical systems are based on three plasmids:

25

- A transfer plasmid containing the genetic sequence packaged into the produced virions. The sequence is flanked by inverted terminal repeats to be replicated and inserted into the capsid. This plasmid may also contain a gene of interest driven by a promoter, a 3' untranslated region (3'UTR) and a polyadenylation sequence.
- A packaging plasmid, comprising the Rep and Cap genes, often under the control of a strong promoter.
- A helper plasmid, which supplies the remaining genes required for viral production. In the case of an AAV, these may be E4, E2a and VA, and

30

35

optionally E1a and E1b – some of these genes may however be expressed directly in the host cell.

5 Other systems based on two plasmids comprise a transfer plasmid as above, and one plasmid corresponding to both the helper and the packaging plasmid. Such systems allow production of replication deficient viruses in a simplified manner.

10 A third approach developed by the inventors is particularly suited for the screening methods disclosed herein. The packaging and the transfer plasmids are combined into one functional plasmid, which thus provides the Rep and Cap genes and the TR or ITR-flanked genome to be inserted in the virion, but still ensures that the vector is replication deficient. The helper plasmid is as described above, i.e. it supplies the remaining genes required for viral production. In particular embodiments, the production system thus comprises a cell, a plasmid providing the Rep and Cap genes and the TR or ITR-flanked genome, and a helper plasmid providing the remaining genes required for viral production.

Diversity

20 Using the present methods, it is thus possible to design libraries having a high diversity, as illustrated in example 1. The diversity will typically increase proportionally to the number of polypeptide fragments of candidate polypeptides. It is also possible to further increase the library diversity by designing different polynucleotides for each polypeptide fragment. Likewise, polynucleotides encoding mutant polypeptide fragments, corresponding to the candidate polypeptides comprising one or more mutated residues compared to the native polypeptide, may also be included in the library.

25 In some embodiments, it may be desirable to obtain a library of viral particles with polypeptide fragments of a small subset of proteins, being as low as just one protein, in order to systematically map the functional domains of said protein. This approach was successfully used by the inventors to identify regions of APP and Tau, proteins known to be involved in Alzheimer's disease, which confer retrograde transport, as shown in example 3.

Designing and manufacturing viral vectors and viral particles with a desired property

The present disclosure thus also provides methods for designing and manufacturing viral vectors with a desired property, said method comprising steps i) to v) as described herein above, and further comprising the steps of:

- 5 vi) retrieving a fraction of viral vectors from the amplification system of step v) b) above, or retrieving at least part of the viral particles from the production system of step v) b) above, and contacting a cell population with said retrieved viral vectors or viral particles;
- vii) monitoring marker expression and selecting the cells wherein marker
10 expression follows a desired pattern;
- viii) identifying the barcode polynucleotides expressed in the cells selected in step vii), thereby identifying the candidate polynucleotides responsible for the desired property and the corresponding candidate polypeptides;
- ix) designing a viral vector comprising a modified capsid gene, wherein the
15 modified capsid gene comprises one of the candidate polynucleotides identified in step viii).

In some embodiments, the viral vector of step ix) is amplified in an amplification system, as described herein above.

20

In some aspects, the viral vector further comprises a transgene to be delivered to a host cell and is produced in a production system, thereby obtaining a viral particle having the desired property.

25

Also provided is a method of manufacturing a viral particle having a desired property, said method comprising steps i) to v) above, and further comprising the steps of:

- vi) retrieving at least part of the plurality of viral vectors from the amplification system of step v) b) or retrieving at least part of the plurality of viral particles from the production system of step v) b);
- 30 vii) contacting a cell population with the retrieved viral vectors or viral particles obtained in step vi);
- viii) monitoring marker expression and selecting the cells wherein marker expression follows a desired pattern;

- ix) identifying the barcode polynucleotides expressed in the cells identified in step viii), thereby identifying the candidate polynucleotides responsible for the desired property and the corresponding candidate polypeptides;
- x) designing a viral vector comprising a modified capsid gene, wherein the modified capsid gene comprises one of the candidate polynucleotides identified in step ix);
- xi) producing the viral vector of step x) in an amplification system or in a production system, thereby obtaining the viral particle having the desired property.

Accordingly, are provided methods of identifying the candidate polypeptides responsible for a desired property, and using said candidate polypeptides to design and manufacture viral vectors and particles having a desired property.

Desired property

As will be evident from the examples below, the desired property may be any property which is desirable for a given application. The present methods thus allow identification, and subsequent design and production of corresponding viral vectors and viral particles, based on the identification of the candidate polypeptides which when introduced in a capsid confer one of more of the following properties:

- affinity to a given cellular structure, such as a structure specific to a given type of cells, such as a synapse, or to a structure specific to a given cellular event, such as cellular division, cell differentiation, neuronal activation, inflammation or tissue damage;
- improved transport properties, such as improved transport in the environment surrounding the host cell or improved transport across the blood-brain barrier;
- increased ability to escape metabolism liver;
- increased ability to evade the immune system;
- increased ability to trigger the immune system.

The present methods can thus be used to identify polypeptide fragments which, when inserted in the capsid of a viral particle, can for example modify tropism of the particle, its infectivity, or its transport in the environment surrounding an injection site.

The inventors have, using the present methods and as illustrated in the examples, selected polypeptides known to have affinity to synapses to design a viral vector library. The library was then screened to identify the polypeptides which confer significantly improved infectivity compared to a mutated capsid having lost tropism for HEK293T cells in vitro. From the same library, modified capsids were identified having improved infectivity toward primary cortical neurons, or improved retrograde transport capacity.

The present disclosure thus also provides a method for improving a desired property to a viral particle comprising a capsid modified by insertion of said polypeptide therein, said method comprising steps i) to v) above, and further comprising the steps of:

- vi) retrieving at least part of the plurality of viral vectors from the amplification system of step v) b) or retrieving at least part of the plurality of viral particles from the production system of step v) b);
- vii) contacting a cell population comprising target cells with the retrieved viral vectors or viral particles obtained in vi) and with a reference viral vector or a reference viral particle comprising a marker;
- viii) monitoring and comparing marker expression in the target cells;
- ix) identifying the candidate polynucleotides in the target cells having an expression profile of the marker corresponding to an improvement of the desired property.

The reference viral vector or the reference viral particle may preferably be identical to the modified viral vector or modified viral particle, with the notable exception of the capsid. Preferably, the capsid of the reference viral vector or particle is not modified.

Cell population and target cells

In a subsequent step, the viral particle library is tested in a cell population. The nature of the desired property will be important for determining the nature of the cell population which is to be contacted with the plurality of viral particles of the library, in order to identify the particles which have the desired property. For instance, if the desired property is increased tropism toward specific types of cells, e.g. of the central nervous system, the cell population must comprise said specific types of cells.

The library of particles may be contacted with a cell population in vitro or in vivo. The library of viral particles may for example be injected in an animal or a human, for example at a specific injection site, or it may simply be contacted with a cell culture.

5 It is then possible to monitor marker expression and select the cells where marker expression follows the expected or desired pattern. This can be done by methods known in the art. For example, if a fluorescent marker is used, the cells may be monitored for fluorescent emission, following which RNA is extracted from the cells in order to identify the expressed barcodes. RNA may also just be extracted from the
10 target cells, and the barcode polynucleotides may subsequently identified by sequencing.

Since the barcode polynucleotides are each operably linked to a single polypeptide fragment, identification of the barcode polynucleotide enables identification of the
15 polypeptide fragments responsible for the desired expression pattern. Said polypeptide fragments may then be used to design viral vectors encoding modified viral particles with a modified capsid, by inserting the polynucleotide encoding the relevant polypeptide fragment in the capsid so that it is displayed on the surface of the particle, thereby altering the properties of the native capsid, as described herein above. The
20 modified viral vectors or particles do not require the presence of the barcode polynucleotide. Alternatively, the viral vectors or viral particles displaying the desired properties may be retrieved directly from the cell population in which they are tested.

The modified viral particles may then be amplified in an amplification system and/or
25 produced in a production system, as described herein above.

Delivering a transgene to a target cell

The methods disclosed herein may thus be used to design modified viral particles comprising a capsid modified by insertion of a polypeptide conferring a desired
30 property, where the modified viral particles are particularly well suited for delivery of a transgene to a target cell.

By the term "transgene" is to be understood as referring to a polynucleotide comprising a gene isolated from one organism and to be introduced into a different organism. A
35 transgene is thus not native to the target cell.

Accordingly, the present modified viral particles may encapsulate a transgene to be delivered to a target cell. Upon injection of the modified viral vector or viral particle into an injection site, or upon contact with a cell population comprising the target cell, the transgene is delivered to the target cell. It is to be noted that the target cell does not need to be in the vicinity of the injection site, provided that the modified viral vector or modified viral particle is capable of being transported to the target cell from the injection site. The term "injection site" should be understood in its broad sense, i.e. it may refer to a site of an organism to which the vectors or particles are injected, or it may simply refer to a cell population comprising the target cells which it is desirable to infect with the vectors or particles upon contact therewith.

Thus are also disclosed herein modified viral particles for delivering a transgene to a target cell, comprising a modified capsid gene and a transgene to be delivered to the target cell. Viral vectors encoding such viral particles are also disclosed.

Accordingly, the use of the modified viral particles disclosed herein, which may comprise a modified capsid as detailed further below, for a method of treatment comprising or consisting of a step of gene therapy is also provided.

Preferably, the modified viral particles present improved properties compared to an unmodified viral particle, i.e. a viral particle which comprises a native, unmodified capsid gene. The improved properties may be any of the properties listed herein above.

The modified viral particle may be derived from an adeno-associated virus (AAV), a retrovirus, a lentivirus, an adeno-virus, a herpes simplex virus, a bocavirus or a rabies virus.

The modified viral particle may comprise a modified capsid as disclosed herein, in particular a modified capsid comprising or consisting of a polypeptide which comprises or consists of a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the most one amino acid residue has been deleted, modified or replaced. In other embodiments, the modified capsid comprises a polypeptide which is a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the most two amino acid residues have been deleted, modified or replaced. In other embodiments, the modified capsid comprises a polypeptide which is

a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the most three amino acid residues have been deleted, modified or replaced. The variant may be a variant of of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, 5 SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, 10 SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or of SEQ ID NO: 50.

Transgene

15 The nature of the transgene will typically be directed by the result that is desired.

The transgene may be a gene useful for gene therapy, for example a “replacement” or “correction” gene replacing a gene which is deficient in an individual. The transgene may also encode a protein or a transcript which upon expression may compensate for 20 a deficient mechanism in the target cell. The transgene may also be used to knock down or reduce expression of a gene causing a disease. This can be by way of inhibition if the transgene codes for a silencing RNA. Below are listed some examples of genes that may be targeted by transgenes using the present vectors to treat or alleviate symptoms of diseases of the nervous system, by way of illustration.

25 The transgene may be a gene involved in the synthesis of dopamine, which may be useful to alleviate symptoms of Parkinson’s disease, for examples genes encoding tyrosine hydroxylase, aromatic amino-acid decarboxylase (AADC), GTP-cyclohydrolase 1 (GCH1) or vesicular mono-amine transporter 2 (VMAT2). The 30 transgene may also be a neuroprotective gene, which it may be desirable to express for example in patients suffering from Parkinson’s disease, such as Nurr1, GDNF, neurturin (NRTN), CNDF or MANF. The transgene may upon expression result in knock-down or correction of genes causing Parkinson’s disease, e.g. alpha-synuclein (SNCA), LRRK2, Pink1, PRKN, GBA, DJ1, UCHL1, MAPT, ATP13A2 or VPS35.

35

Examples of genes that may be knocked down or corrected in Alzheimer's patients are APP, MAPT, SPEN1 and PSEN2. In Huntington's disease patients, the HTT gene (coding for huntingtin) may be knocked down or corrected by delivery of the transgene. In patients suffering from spinocerebellar ataxia, ataxin 1, 2, 3, 7 or 10, PLEKHG4, 5 SPTBN2, CACNA1A, IOSCA, TTBK2, PPP2R2B, KCNC3, PRKCG, ITPR1, TBP, KCND3 or FGF14 may be knocked down or corrected upon delivery and expression of the transgene. In multiple system atrophy, SNCA or COQ2 may be relevant targets of for knock-down or correction. In amyotrophic lateral sclerosis, the transgene may lead to overexpression or correction of C9orf72, SOD1, TARDBP or FUS. SMN1, SMN2, 10 UBA1, DYNC1H1 or VAPB are targets for knock-down or correction in spinal muscular atrophy patients. DMD is a target for overexpression or correction in Duchenne muscular dystrophy. The transgene may allow for correction of ABCA13, C4A, DGCR2, DGCR8, DRD2, MIR137, NOS1AP, NRXN1, OLIG2, RTN4R, SYN2, TOP3B, YWHAE or ZDHHC8 in schizophrenic patients. Galanin, NPY, somatostatin or KCNA1 may be 15 targets for overexpression in epileptic patients. The transgene may enable overexpression of p11, PDE11a, channel rhodopsins or chemogenetic receptors in individuals suffering from depression.

The transgene may in other embodiments be an immunogenic agent, e.g. the modified 20 viral particle may be used to target cells of the immune system to immunise an individual to a given epitope.

Disclosed herein are modified viral particles comprising a modified capsid, wherein the modified capsid comprises or consists of a polypeptide comprising or consisting of a 25 sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 50. Also disclosed are modified viral vectors encoding said modified viral particles. In one embodiment, the modified capsid comprises a polypeptide comprising or consisting of 30 SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, 35 SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41,

SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46,
SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

Such modified capsids may comprise any of the above polypeptide fragments, or
5 variants thereof, i.e. modified polypeptide fragments, wherein at the most one, such as
at the most two, such as at the most three amino acid residues have been deleted,
modified or replaced.

Accordingly, in some embodiments, the modified capsid comprises a polypeptide which
10 comprises or consists of a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the
most one amino acid residue has been deleted, modified or replaced. In other
embodiments, the modified capsid comprises a polypeptide which is a variant of SEQ
ID NO: 1 to SEQ ID NO: 50, wherein at the most two amino acid residues have been
deleted, modified or replaced. In other embodiments, the modified capsid comprises a
15 polypeptide which is a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the most
three amino acid residues have been deleted, modified or replaced. The variant may
be a variant of of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID
NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10,
SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15,
20 SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20,
SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25,
SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30,
SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35,
SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40,
25 SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45,
SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or of SEQ ID NO:
50.

In some embodiments, the polypeptide is encoded by a polynucleotide comprising or
30 consisting of a sequence selected from the group consisting of SEQ ID NO: 51 to SEQ
ID NO: 100. In some embodiments, the polypeptide is encoded by a polynucleotide
comprising or consisting of a sequence selected from SEQ ID NO: 51, SEQ ID NO: 52,
SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57,
SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62,
35 SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67,
SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72,

SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77,
SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82,
SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87,
SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92,
5 SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97,
SEQ ID NO: 98, SEQ ID NO: 99 or SEQ ID NO: 100.

As is known in the art, the transgene may be inserted in the viral genome, i.e. between
the terminal repeat sequences, such as long terminal repeats or inverted terminal
10 repeat sequences, delimiting the viral genome.

Target cells

The cells to be targeted for transgene delivery are preferably cells in which expression
of the transgene is desired. The target cells may for example be neurons, such as
cortical neurons and/or neurons of the hippocampus and/or the entorhinal cortex and/or
15 the cerebellum and/or of the spinal cord and/or at the epileptic focus and/or of the
nucleus accumbens and/or of the Habenula; glial cells, in particular in the caudate-
putamen and/or the substantia nigra and/or the cerebral cortex and/or of the infarct
area; DA neurons, in particular of the substantia nigra and the ventral tegmental area;
or muscle myocytes.

20

Libraries of modified viral vectors can be screened as described above, where the
improved property that is selected for is increased infectivity and/or tropism for a target
cell, in particular the target cells listed above.

Methods of treatment

25 Also provided herein is a modified viral vector as disclosed anywhere herein, or a
modified viral particle as disclosed herein, for use in a method of treatment or
prophylaxis of a disorder.

The modified viral particle displays a polypeptide which may for example result in
30 increased infectivity of cells to be targeted for delivery of a transgene which may be
useful for treating or preventing said disorder.

Accordingly, herein is disclosed a method of treatment or prophylaxis of a disease or
disorder, comprising the steps of administering a modified viral vector or a modified

viral particle as described herein to a subject in need thereof, said modified viral vector or particle comprising a transgene. Preferably the modified viral particle has increased tropism and/or infectivity for the target cell to which the transgene is to be delivered than a corresponding, unmodified viral particle with an unmodified capsid.

5

The modified viral particle may comprise a modified capsid as disclosed herein, in particular a modified capsid comprising or consisting of a polypeptide which comprises or consists of a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the most one amino acid residue has been deleted, modified or replaced. In other embodiments, the modified capsid comprises a polypeptide which is a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the most two amino acid residues have been deleted, modified or replaced. In other embodiments, the modified capsid comprises a polypeptide which is a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the most three amino acid residues have been deleted, modified or replaced. The variant may be a variant of of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or of SEQ ID NO: 50.

25

The subject in need may be a subject suffering from, suspected of suffering from, or at risk of suffering from a disease or disorder.

In some embodiments, the disease is Parkinson's disease. The transgene may encode tyrosine hydroxylase, aromatic amino-acid decarboxylase (AADC), GTP-cyclohydrolase 1 (GCH1) or vesicular mono-amine transporter 2 (VMAT2); preferred target cells for such embodiments are neurons and or glial cells in the caudate-putamen and/or the substantia nigra. The transgene may lead to overexpression of neuroprotective genes, such as Nurr1, GDNF, neurturin (NRTN), CNDF or MANF; preferred target cells for such embodiments are neurons and or glial cells in the caudate-putamen and/or the substantia nigra. The transgene may lead to knock-down

35

or correction of alpha-synuclein (SNCA), LRRK2, Pink1, PRKN, GBA, DJ1, UCHL1, MAPT, ATP13A2, VPS35; preferred target cells for such embodiments are DA neurons of the substantia nigra and the ventral tegmental area.

5 In other embodiments, the disease is Alzheimer's disease, and the transgene leads to knock-down or correction of APP, MAPT, SPEN1 or PSEN2. Preferred target cells for such embodiments are neurons of the hippocampus and the entorhinal cortex.

10 In other embodiments, the disease is Huntington's disease and the transgene knocks down or corrects HTT. Preferred target cells for such embodiments are neurons and or glial cells in the caudate-putamen and/or the cerebral cortex.

15 In other embodiments, the disease is spinocerebellar ataxia and the transgene knocks down or corrects ataxin 1, 2, 3, 7 or 10, PLEKHG4, SPTBN2, CACNA1A, IOSCA, TTBK2, PPP2R2B, KCNC3, PRKCG, ITPR1, TBP, KCND3, or FGF14. Preferred target cells for such embodiments are neurons of the cerebellum.

20 In other embodiments, the disease is multiple system atrophy and the transgene knocks down or corrects SNCA or COQ2. Preferred target cells for such embodiments are neurons and or glial cells in the caudate-putamen and/or the substantia nigra and/or the cerebral cortex

25 In other embodiments the disorder is amyotrophic lateral sclerosis and the transgene leads to overexpression or correction of C9orf72, SOD1, TARDBP or FUS. Preferred target cells for such embodiments are neurons of the spinal cord.

30 In other embodiments, the disorder is spinal muscular atrophy and the transgene leads to knock-down or correction of SMN1, SMN2, UBA1, DYNC1H1 or VAPB. Preferred target cells for such embodiments are neurons of the spinal cord.

In other embodiments, the disorder is Duchenne muscular dystrophy and the transgene leads to overexpression or correction of DMD. Preferred target cells for such embodiments are muscle myocytes.

35 In other embodiments, the disorder is schizophrenia and the transgene leads to correction of ABCA13, C4A, DGCR2, DGCR8, DRD2, MIR137, NOS1AP, NRXN1,

OLIG2, RTN4R, SYN2, TOP3B, YWHAE or ZDHHC8. Preferred target cells for such embodiments are cortical neurons.

5 In other embodiments, the disorder is epilepsy and the transgene leads to overexpression of galanin, NPY, somatostatin or KCNA1. Preferred target cells for such embodiments are neurons at the epileptic focus.

10 In other embodiments, the disorder is depression and the transgene leads to overexpression of p11, PDE11a; preferred target cells for such embodiments are neurons of the nucleus accumbens; or the transgene leads to overexpression of channel rhodopsins or chemogenetic receptors; preferred target cells for such embodiments are neurons of the Habenula.

Drug screening

15 The modified viral vectors and particles obtainable by the methods disclosed herein may also be useful for a number of additional applications, including drug screening.

In one aspect is provided a method for identifying a drug having a desired effect, said method comprising the steps of:

- 20 a) Providing a candidate drug;
b) Administering the candidate drug to a cell;
c) Providing a modified viral particle comprising a modified capsid allowing delivery of the viral particle to the cell of b) and a marker polynucleotide;
d) Monitoring and comparing expression and/or localisation of the marker
25 polypeptide in the presence and absence of the candidate drug;
thereby determining whether the candidate drug has an effect on the expression of the marker polynucleotide.

30 The modified viral particle may comprise a modified capsid as disclosed herein, in particular a modified capsid comprising or consisting of a polypeptide which comprises or consists of a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the most one amino acid residue has been deleted, modified or replaced. In other embodiments, the modified capsid comprises a polypeptide which is a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the most two amino acid residues have been deleted, modified or
35 replaced. In other embodiments, the modified capsid comprises a polypeptide which is

a variant of SEQ ID NO: 1 to SEQ ID NO: 50, wherein at the most three amino acid residues have been deleted, modified or replaced. The variant may be a variant of of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, 5 SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, 10 SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or of SEQ ID NO: 50.

Functional mapping of protein domains

15 The modified viral vectors and particles obtainable by the methods described herein can be used to perform functional mapping of protein domains. This is illustrated in example 5.

By the present methods, polypeptide fragments of polypeptides known to be or 20 suspected of being involved in a given mechanism or disorder may be used to manufacture a library of modified capsids, where the modified capsids display different regions of the polypeptides.

Accordingly is provided herein a method of identifying one or more regions of a 25 polypeptide conferring a desired property to a viral particle comprising a capsid modified by insertion of said polypeptide therein, said method comprising steps i) to v) above and further comprising the steps of:

- vi) retrieving at least part of the plurality of viral vectors from the amplification system of step v) b) or retrieving at least part of the plurality of viral particles 30 from the production system of step v) b);
- vii) contacting a cell population comprising target cells with the retrieved viral vectors or viral particles obtained in vi) and with a reference viral vector or a reference viral particle comprising a marker;
- viii) monitoring and comparing marker expression in the target cells;

- ix) identifying the candidate polynucleotides in the target cells having an expression profile of the marker corresponding to the desired property, thereby identifying the region of the polypeptide responsible for said property.

5

For such applications, as will be evident to the skilled person, the higher the number of polypeptide fragments displayed by the capsid library and/or the greater the overlap between the individual polypeptide fragments is, the more precise the functional mapping will be. Accordingly, in some embodiments, each polypeptide is represented by a number of polypeptide fragments in such a way that the polypeptide fragments overlap by all but one amino acid residue.

10

Examples

15

Example 1 - Design and generation of highly diverse AAV library, and screening for retrograde transport function

Materials and methods

AAV library backbone plasmid cloning

20

The backbone plasmid used for cloning the barcoded modified AAV capsids was developed from a self-complementary AAV (scAAV) vector expressing GFP (pscAAV-GFP²⁴) and pDG²⁵ (with deletions of Adenovirus genes VA, E2A and E4). The final plasmid contained an eGFP expression cassette driven by a CMV promoter and the wild type AAV2 genome with the mouse mammary tumor virus (MMTV) promoter. First, the XbaI, BsiWI and MluI sites were inserted between XhoI and HindIII sites in pscAAV-GFP [Addgene #32396]. Second, an NheI site was introduced between sequences of N587 and R588 of VP1 capsid protein by overlap extension PCR²⁶ using modified pDG as template. Besides the NheI site, the final PCR product also contained a BsiWI and a MluI site to facilitate subsequent cloning and LoxP-JTZ17 insertion (for Cre recombination and Next Generation sequencing of the final library). Finally, the modified pscAAV-GFP was digested using XbaI and MluI, the overlap extension PCR product was digested with MluI and BsiWI, and pDG was digested by BsiWI and XbaI. The three DNA fragments were then ligated to acquire the final backbone plasmid for the AAV library.

30

Selecting proteins for peptide display

Candidates of peptides to be inserted were derived from known neuron-related proteins. 131 proteins were selected, belonging to five categories; neurotropic viruses, lectins, neurotrophins, neurotoxins, and neuronal proteins. The candidate protein selection was based on known interaction between the proteins and neurons in binding and different stages of AAV infection and replication process (e.g. internalization, endosomal trafficking, nuclear import, etc.). Peptides were designed to be incorporated between N587 and R588 of VP1 capsid protein ¹¹, a site that previously was reported to tolerate insertion of large peptides ^{14, 27} and blocks heparan sulfate proteoglycan binding ^{12, 13}. Four different peptide conformations were designed as: A-14aa-A, A-22aa-A, A5-14aa-A5, G4S-14aa-G4S. They contained two lengths of peptides of 14 or 22 amino acid (aa) residues and were flanked by either a spacer of one amino acid of alanine (A) or a short linker (A5 or G4S) ^{28, 29}. All possible unique peptides of 14 or 22 aa from the candidate proteins were identified and generated by a sliding window approach using R program. The peptide library was reverse translated to oligonucleotides using codon optimization for high-level expression in HEK293 cells.

Array oligonucleotide synthesis and amplification

The final oligonucleotide pool containing 92,918 unique oligonucleotides was synthesized using 90k DNA array (Custom Array), which encoded all possible unique peptides from A-14aa-A, and selected peptides from the other three peptide conformations.

The oligonucleotide pool was amplified and prepared for Gibson assembly in an emulsion PCR with long extension time to reduce PCR artifacts ^{17, 30}.

PCR mix was prepared using PhusionTM Hot Start II High-Fidelity DNA polymerase (ThermoFisher) according to manufacturer's recommendation with the exception of adding 0.5 µg/µl BSA (NEB). Briefly, 9 volumes of an oil surfactant mixture (92.95 % of Mineral oil, 7 % of ABIL WE and 0.05 % of Triton X-100) was added to the PCR mixture and an emulsion was created by homogenizing for 5 min at a speed of 4 m/s using MP FastPrep-24 Tissue and Cell Homogenizer (MP Biomedicals). The PCR program used for the emulsion PCR was; 1 cycle of 30s at 98°C, 30 cycles of 5s at 98°C, 30s at 65°C and 2 min (8-fold of regular extension time) at 72°C and finally 1 cycle of 5 min at 72°C. After the PCR, the emulsion was broken by adding 2 volumes of isobutanol to each tube, the aqueous phase containing the PCR product was

separated by a short centrifugation (16,000g for 2 min) and finally purified using E.Z.N.A.TM Cycle Pure Kit (Omega).

AAV library cloning and barcoding

Gibson assembly was used to insert the oligonucleotide pool (into the capsid gene located outside of the ITR's) and barcodes (downstream of GFP located inside of the ITR's) to generate a barcoded AAV plasmid library (Fig 1). A one cycle PCR was performed to generate barcoded fragments with overhangs for Gibson assembly. Barcode length was 20 nucleotides and defined as ambiguity nucleotides by using the sequence V-H-D-B (IUPAC ambiguity code) repeated five times and flanked by static sequences for binding. Oligos also contained a LoxP-JTZ17 site, for facilitating subsequent Cre recombination. A 40 µl Gibson Assembly reaction (NEB) was performed to insert oligonucleotide pool and barcoded fragments into 200 ng of digested vector, using a molar ratio of 1.3:1.3:1. The reaction was incubated for 1 h at 50 °C and purified using DNA Clean & Concentrator-5 (Zymo Research). 1 µl (37.4 ng) purified Gibson assembly product was transformed into 20 µl MegaX DH10BTM T1R ElectrocompTM (Thermo Fischer Scientific) cells according to the manufacturer's protocol. 5 individual transformations were performed and pooled into one tube. A small fraction of the transformed bacteria was plated on agar plates to validate the transformation efficacy. 10 clones were picked from the plates and oligonucleotide and barcode insertion was validated by restriction enzyme digestion using Bsp120I, BsrGI, and SpeI (Fastdigest, Thermo Fischer Scientific). The none plated transformed bacteria were grown o.n as a maxi prep and purified using ZymoPURE Plasmid Maxiprep Kit (ZYMO Research).

AAV production-Library

HEK293T cells were seeded in 175 cm cell culture flasks to achieve 60-80% confluency before transfection. 25 µg, 250 ng or 25 ng of the AAV plasmid library, and 46 µg of pHGTI-Adeno1¹⁸ were transfected using calcium phosphate. The molar ratio of AAV plasmid library: pHGTI-Adeno1 were 1:1, 0.01:1 (30cpc), or 0.001:1 (3cpc) respectively. The 1:1 ratio was expected to receive a chimeric AAV library, in which each single particle likely contained chimeric mutation capsid proteins. The ratio of 0.01:1 and 0.001:1 was assumed to make cells receive approximately one member from the AAV plasmid library⁶.and subsequently to receive a clean AAV library, in which each single particle was consisted of same mutation capsid proteins and a consistent barcode. Viral libraries were harvested and purified using iodixanol gradient

as previously described³¹. The AAV genomic titer was determined by quantification of vector DNA as described using real time PCR³².

Sequencing AAV plasmid library

To facilitate paired-end Illumina sequencing of the plasmid library, a part of the AAV
5 plasmid was excised by Cre-recombinase to bring inserted peptide sequence and
barcode closer together (Figure 1). 1.5 µg DNA was incubated with 6U Cre-
recombinase (NEB) in a volume of 100 µl at 37°C for 1h. The reaction was terminated
at 70°C for 10 minutes and purified by DNA Clean & Concentrator-5 (ZYMO Research).
The product was digested using BsiWI and MunI, ran on agarose gel and the desired
10 fragment was selected and purified using Zymoclean Gel DNA Recovery (Zymo
Research). The gel extraction product was subjected to PreCR Repair using PreCR
Repair Mix (NEB). In 50 µl reaction, 50 ng DNA, 100 µM dNTPs and 1X NAD⁺ was
incubated in 1X ThermoPol Buffer at 37°C for 20 min. 5 µl PreCR repaired DNA was
15 PCR:ed with P5/P7 Illumina primers P11 and mix of P12, P13, P14, P15 using Phusion
HSII (Thermo Fischer Scientific). Again, to reduce recombination between the
fragments in PCR, an emulsion PCR was performed. The emulsion was created as
previously described. The PCR cycles were 1 cycle of 30s at 98°C, 18 cycles of 5s at
98°C, 15s at 63°C and 3min (8-fold of regular extension time) at 72°C, and 1cycle of 5
20 min at 72°C. The emulsion was broken, the product was purified as previously
described and a PreCR Repair was performed. 5 µl PreCR repaired DNA from the
previous step was used in the next emulsion PCR to add Nextera XT Indexes, using
Nextera™ XT Index Kit (Illumina). The PCR program was; 1 cycle of 1 min at 98°C, 10
cycles of 15s at 98°C, 20s at 65°C and 3min (8-fold of regular extension time) at 72°C,
and 1cycle of 5 min at 72°C. The product from the Nextera XT Index emulsion PCR
25 was purified and size selected using SPRIselect Kit (Beckman Culter). The purified and
indexed PCR products were sequenced using Illumina MiSeq Reagent Kit v2 (Illumina)
with 150bp paired end sequencing.

Sequencing RNA-derived barcode

Total RNA was isolated from brain tissue, primary neurons and HEK293T cells using
30 PureLink™ RNA Mini Kit (Thermo Fischer Scientific) according to the manufacture's
protocol. RNA samples were incubated with DNase I (NEB) to remove DNA
contamination. 5µg RNA was incubated with 1 unit DNase I in 1X DNase I Reaction
Buffer to a final volume of 50µl and incubated at 37°C for 10 minutes. Subsequently,
0.5µl of 0.5M EDTA was added and then heat inactivated at 75°C for 10 minutes.
35 DNase I-treated RNA was reverse transcribed to cDNA using qScript cDNA Synthesis

Kit (Quanta) according to manufacturer's recommendations. 2 µl cDNA was then amplified by PCR using primers P16 and P17. The PCR program was 1 cycle of 30 s at 98°C, 35 cycles of 5 s at 98°C, 15 s at 65°C and 30 s at 72°C followed by 1 cycle of 5 min at 72°C. The PCR products containing the barcodes were purified by gel extraction using Zymoclean Gel DNA Recovery Kit (Zymo Research). 20 ng purified DNA was subjected to a P5/P7 Illumina adapter PCR using primers P18 and an equal mix of P12, P13, P14, P15. The PCR cycles were 1 cycle of 30 s at 98°C, 10 cycles of 5 s at 98°C, 15 s at 65°C and 30 s at 72°C, followed by 1 cycle of 5 min at 72°C. The PCR products were purified by gel extraction as previously described. Subsequently, a Nextera XT Index PCR using Nextera™ XT Index Kit (Illumina) was performed. The PCR program was; 1 cycle of 1 min at 98°C, 6 cycles of 15 s at 98°C, 20 s at 65°C and 1 min at 72°C, followed by 1 cycle of 5 min at 72°C. The PCR products were purified using SPRIselect (Beckman Culter). The purified PCR products were sequenced using Illumina NextSeq™ 500/550 Mid Output Kit v2 (Illumina) with 75bp paired end reads.

15 *Sequencing viral library*

Two AAV batches were produced (for production method see "AAV production-capsid validation studies"), one batch with 100-fold dilution (30cpc) of plasmid containing the capsids and barcode and one 1000-fold dilution (3cpc) of the same plasmid (corresponding to 250ng and 25ng in "AAV production-Library"). After production, purification and titration, both batches were DNaseI treated and lyzed by Proteinase K. The viral lysate was subjected to two rounds of PCR to add Illumina compatible P5/P7 sequences and NexteraXT Indexes and then purified using SPRIselect (Beckman Culter). The purified and indexed samples were sequenced using Illumina NextSeq™ 500/550 Mid Output Kit v2 (Illumina) with 75 bp paired end reads.

25 *Transduction of human ES cells*

Human ES cells were differentiated into dopaminergic progenitor cells³⁶. 42 days after the differentiation started, cells were transduced with scAAV-GFP using 5×10^8 gc/well and incubated o.n. 72 hours post transduction, cells were fixed with 4% PFA and stained for Map-2, Tyrosine Hydroxylase and DAPI (see Immunohistochemistry). In total 29 different AAV-capsids were validated. Cells were analysed in Cellomics, Trophos Plate runner and Confocal microscope.

Data assessment workflow

A complete interaction free workflow was implemented using the R statistical package together with a number of packages from the Bioconductor repository. From these

scripts, a number of broad-utility external applications (bbmap, Blast, Starcode³⁷, bowtie2, samtools, Weblogo 3 and Hammock³⁸) were called and output returned to R for further analysis. This is publically available as a Git repository at <https://bitbucket.org/MNM-LU/aav-library> and as a self-sustained Docker image
5 Bjorklund/aavlib:v0.2 .

In brief; barcode and sequence identification, trimming and quality filtration was conducted using the bbmap software package³⁹, which allows for kmere matching of known backbone sequences against the reads. As a vast majority of barcode reads
10 were sequenced to the length of 20 with most barcodes of a deviating length ending up being 19 bp long, for all analysis in this study, length filtration of $18 \leq BC \leq 22$ was applied.

The peptide sequence fragments were similarly isolated using the bbmap software
15 package, but this time without any application of length restrictions and then aligned to the reference peptides using blastn.

The key component of the R-based analysis framework is a parallelized implementation of the MapReduce programming philosophy^{40, 41}. For more details on
20 this process please refer to¹⁷. In this process Bowtie2 was first utilized to align the synthesized peptide stretches to the protein reference sequences, then blastn was used to map the sequenced fragments to the peptides and finally a purpose-built R workflow was implemented so select the pure sequencing results filtering out
25 erroneous reads generated through template switching in the PCR based sample preparation and to identify mutations resulting from the CustomArray oligonucleotide synthesis.

From the *in vitro* and *in vivo* samples, the AAV-derived barcodes were identified by targeted sequencing and mapped back to the respective fragments and their origin
30 within the selected proteins. Efficacy of transport was then quantified and mapped with identification of the most efficient candidates. In parallel, the barcode count together with peptide aa sequence was fed into the Hammock tool³⁸ and consensus motifs were visualized using Weblogo 3.

Results

Generation of a viral vector library

As a first step, we identified from the literature 131 proteins with documented affinity to synapses (Figure 1A). They fall into four major groups; viral-derived (capsid and envelope) proteins, host derived proteins (neurotrophins and disease-related proteins e.g., Tau), neurotoxins and lectins. NCBI reference sequences of the 131 proteins were translated into amino acid sequences and computationally digested into 14aa long polypeptides with a 1aa shifting sliding window approach (1. in Figure 1B). The 61 314 peptides generated in total consisted of 44 708 unique polypeptides. Three alternative linkers were added to the polypeptides; a single Alanine (called 14aa), a rigid linker with 5 Alanine residues (14aaA5) and a flexible linker with the aa sequence GGGGS (14aaG4S) (2. in Figure 1B). A last group of aa peptides were similarly generated with a 22aa length and a single Alanine linker (called 22aa). A total of 92 343 aa sequences were then codon optimized for expression in human cells and overhangs added to the ends to allow for directional scar-less Gibson-assembly cloning into the AAV2 Cap gene at the position N587 (3. in Figure 1B). All resulting oligos with the total length of 170 bp were synthesized in parallel on a CustomArray oligonucleotide array.

Generation of highly diverse AAV capsid library for the BRAVE approach

To develop the AAV library for the BRAVE approach where peptides are displayed at N587 and peptide-associated barcodes simultaneously inserted in the AAV-genome UTR, we first generated a novel backbone plasmid. In this backbone plasmid, we combined the AAV packaging genes (Rep, Cap and AAP) under the control of the MMTV promoter and the GFP expression cassette flanked by mutated inverted terminal repeats (ITR) forming a gutted self-complementary AAV genome^{15, 16}.

To incorporate peptide sequences, we introduced an NheI site at amino acid N587 of VP1 capsid protein¹¹, in which the oligonucleotide pool was inserted. This addition of a restriction site mutates the wild-type AAV2 heparan sulfate proteoglycan binding properties¹² and this variant is hereafter referred to as AAV-MNMnull.

The resulting pool of oligonucleotides was assembled into the AAV production backbone (4. in Figure 1B). A 20bp random molecular barcode (BC) was simultaneously inserted in the 3' UTR of the GFP gene using a 4-fragment Gibson-assembly reaction. Using a uni-directional Cre-recombination approach followed by emPCR-based addition of Illumina sequencing adapters, the entire pool of peptides

was then sequenced using Paired-end sequencing linking the random barcodes to the respective peptide in a Look-Up table (LUT) (5a. in Figure 1B). This approach avoids template switching during PCR and allows for near perfect matching of Barcode to inserted fragment (not shown)¹⁷. The resulting library contained 3 934 570 unique combinations of peptide and barcode containing 90 635 (and thus > 98% recovery) of the designed fragments and close to 50X oversampling with barcodes. The latter is essential for noise filtration, error correction and the mapping of mutations (generated in the custom array) in the bioinformatics process below. In parallel to the LUT generation, the same plasmid library is utilized to generate replication deficient AAV viral vector preps where the peptide is displayed on the capsid surface and the barcode is packaged as part of the AAV genome (5b. in Figure 1B). Multiple parallel screening experiments were then performed both *in vitro* and *in vivo* and after suitable selection (*e.g.*, dissection of the targeted brain region) the mRNA was extracted and the expressed barcodes sequenced. Through the combination of the sequenced barcodes and the LUT, efficacy can be mapped back to the original 131 proteins (6 in Figure 1B) and consensus motifs can be determined using the Hammock, hidden Markov-model (HMM) based clustering approach (7 in Figure 1B).

Production of AAV library

To produce the AAV particle library, the AAV plasmid library was co-transfected together with adenoviral helper plasmid (pHGTI-Adeno1) into HEK293T cells¹⁸. The AAV library plasmid was supplied at a very low concentration to ensure that the producer cell produce few (or a single) capsid variants from the AAV plasmid library^{6, 19} i.e., that each single produced virion consists only of the same mutation capsid proteins and package the correct barcode. We used 3 or 30 copies per cell (cpc) of the AAV plasmid library for production and acquired two AAV libraries with the titer of 2.5×10^{12} and 4.4×10^{10} GC/ml for AAV-MNMlib[30cpc] and AAV-MNMlib[3cpc] respectively. To assess which peptides would allow for correct assembly and genome packaging, we DNase treated both batches (to remove non-packaged genomes), lysed the batches and sequenced the barcodes from the preps separately. Due to the very high diversity of the expressed barcodes, the overlap in barcodes was small between the productions (Figure 1C). However, the absolute majority of all peptides packaged in the 3cpc batch were also recovered in the 30cpc batch (Figure 1C). Injection of the AAV-MNMlib[30cpc] library into the forebrain of adult rats revealed that the inserted peptides confer a striking change in the transduction pattern compared to a AAV2-WT vector with both broader spread of transduction and retrograde transport to the connecting

afferent regions (Figure 1D). To screen for individual novel AAV capsid structures that would allow for efficient retrograde transport in neurons *in vivo*, we then performed a larger experiment where animals received the same library injections into the striatum from either the AAV-MNMLib[30cpc] or the AAV-MNMLib[3cpc] library prep (Figure 1E).
5 8 weeks after injection, total RNA was extracted from the striatal tissue, orbitofrontal cortex (PFC), thalamus (Thal), midbrain region (SNpc) together with the injected Striatal (Str) tissue, followed by RT-PCR and massively parallel sequencing of cDNA from transcribed barcodes. Analysis of the unique peptides recovered at the different
10 dissected regions reveal that $\approx 13\%$ of the inserted peptides promote efficient transduction *in vivo* and $\approx 4\%$ promote retrograde transport.

This example shows that libraries generated by the methods described herein can be used to identify peptides potentially conferring a desired property to a viral particle when displayed on the capsid.

15 *Example 2 - Single-generation BRAVE screening in vitro and in vivo*

Materials and methods

AAV production-capsid validation studies

HEK293T cells were seeded in 175 cm cell culture flasks to achieve 60-80% confluency before transfection. 2 hours before transfection the medium was replaced
20 with 27ml fresh Dulbecco's modified Eagle medium (DMEM) + 10% FBS + P/S. AAV was produced using standard PEI transfection³³ using a three-plasmid system; transfer vector, modified AAV-capsid, and pHGT-1 adenoviral helper plasmid in a 1.2:1:1 ratio. PEI and plasmids were mixed in 3ml DMEM, incubated for 15 min and then added to the cells. 16 hours post transfection 27 ml of medium was removed and equal volume
25 of OptiPRO serum free medium (Thermo Fischer Scientific) +P/S was added. AAVs were harvested 72 hours post transfection using polyethylene glycol 8000 (PEG8000) precipitation and chloroform extraction followed by PBS exchange in Amicon Ultra-0.5 Centrifugal filters (Merck Millipore)³⁴. Purified AAV's were titered using qPCR with primers specific for promoter or transgene.

30 *In vitro infection*

HEK293T cells were cultured in DMEM +10% FBS and P/S. Primary cortical neurons were isolated from embryonic rat (E18) or neonatal mouse of 1 day old as previously described³⁵ and cultured in Neurobasal/B27 medium in black 96-well flat bottom

culture plates (Greiner Bio One). Cells were transduced with 2×10^6 , 2×10^7 and 2×10^8 gc/well. AAV was added to the medium and cells were incubated overnight. AAV containing medium was replaced with fresh medium the following day. Cells were analyzed 72 hours post transduction using Cellomics (Thermo Fischer Scientific) and Plate Runner (Trophos).

Research animals

Adult female Sprague Dawley rats (225-250g) used in this study were purchased from Charles River (Germany) and were housed with free access to food and water under a 12 hours light/12 hours dark cycle in a temperature-controlled room. All experimental procedures performed in this study were approved by the Ethical Committee for Use of Laboratory Animals in the Lund-Malmö region.

Stereotaxic AAV injection

All surgical procedures were performed under general anesthesia with a 20:1 mixture of fentanyl citrate (Fentanyl) and medetomidin hydrochloride (Dormitor), injected intraperitoneally. Targeting coordinates for all stereotaxic infusions were identified relative to the bregma. A small hole was drilled through the skull and the vector solutions were injected with a 25 μ l Hamilton syringe fitted with a glass capillary (60–80 μ m i.d. and 120–160 μ m o.d.) and connected to an automatic infusion pump. Injection was carried out either unilaterally on the right side or bilaterally. The AAV library was injected unilaterally in striatum and at the following coordinates: anteroposterior, +1.2 mm; mediolateral, -2.4 mm; dorsoventral, -5.0/-4.0 mm; toothbar, -3.2 mm. Candidate AAV vectors were infused at anteroposterior, +1.2 mm; mediolateral, -2.4 mm; dorsoventral, -5.0/-4.0 mm and anteroposterior, + 0.0 mm; mediolateral, -3.5 mm; dorsoventral, -5.0/-4.0 mm; toothbar, -3.2 mm. Comparative vector analysis between MNM-004-GFP and AAV-2 Retro-mCherry as well as lateralized comparison between MNM-004-GFP and MNM-004 mCherry were injected bilaterally at anteroposterior, +1.2 mm; mediolateral, -2.4/+2.4 mm; dorsoventral, -5.0/-4.0 mm. For comparative analysis of retrograde transport to midbrain dopaminergic neurons from the striatum between MNM-008, AAV-Retro and AAV-2, TH-cre animals were unilaterally injected with CTE-GFP vectors at two sites at the following coordinates: at anteroposterior, +0.8/-0.2 mm; mediolateral, -3.0/-3.7 mm; dorsoventral, -5.0/-5.0/-4.0 mm. The BLA modulation animals were injected with the MNM-004 vector at anteroposterior, +1.2 mm; mediolateral, -2.4 mm; dorsoventral, -5.0/-4.0 mm; toothbar, -3.2 mm and AAV-8 vectors at anteroposterior, -2.2 mm; mediolateral, +/- 4.8 mm; dorsoventral, -7.4 mm; toothbar, -3.2 mm. For the AAV-library animals, each rat

received 5 μ l of vector solutions at dose of 2.5×10^{10} or 4.4×10^8 vector genomes of AAV library with capsid concentration of 30cpc or 3cpc for AAV plasmid library and normal amounts pHGTI-Adeno1 plasmid. The candidate vector animals received 2 μ l of vector per infusions site while the animals in the BLA modulation animals were infused with 3 μ l of MNM-004 in the striatum and 3 μ l of Cre-inducible DREADDs AAV-8 DIO-hM3Dq/rM3Ds in the BLA. Comparative analysis between vectors injected in the striatum were injected with a viral dose of 2.3×10^{12} vector genomes at a total volume of 1 μ l per deposit site. All infusions were performed at a rate of 0.2 ml/min, and the needle was left in place for an additional 3-min period before it was slowly retracted. Post-surgery, the wound was closed using surgical staples and the animal was placed on a heating mat until awake.

Tissue processing

Eight weeks post injection brains were processed according to subsequent post mortem analysis. For RNA extractions, animals were sacrificed using CO₂, the brains were removed and sliced in the coronal axis into two-millimeter-thick slices using a brain mold. The striatal tissue, orbitofrontal cortex, thalamus and midbrain region were rapidly dissected and frozen individually on dry ice and stored at -80 °C until RNA extraction. For immunohistochemical analysis, the animals were deeply anesthetized by sodium pentobarbital overdose (Apoteksbolaget, Sweden) and transcardially perfused with 50 ml physiological saline solution followed by 250 ml of freshly prepared, ice-cold, 4 % paraformaldehyde (PFA) in 0.1 M phosphate buffer adjusted to pH = 7.4. The brains were then removed and post-fixed further for 2 hours in cold PFA before storing in 25% buffered sucrose for cryoprotection over at least 24 hours until further processing. The remaining PFA fixed brains were cut into 35 mm thick coronal sections using a freezing microtome (Leica SM2000R) and collected into 8 series and stored in anti-freeze solution (0.5 M sodium phosphate buffer, 30 % glycerol and 30 % ethylene glycol) at -20°C.

Immunohistochemistry

For immunohistochemical analysis, tissue sections were washed (3x) with TBS (pH 7.4) and incubated for one hour in 3 % H₂O₂ in 0.5 % TBS Triton solution in order to quench endogenous peroxidase activity and to increase tissue permeability. Following another washing step, the sections were blocked in 5 % bovine serum and incubated for one hour and subsequently incubated with primary monoclonal antibodies overnight. To evaluate GFP expression, immunohistochemistry was performed on brain sections using primary antibody of chicken anti-GFP (1:20000; ab13970, Abcam),

rM3Ds expressing neurons were identified by staining for the HA-tag (mouse anti-HA, Covance Research Products Inc Cat# MMS-101R-200 RRID:AB_10064220, 1:2000). hM3Ds expressing neurons were identified by staining for mCherry (goat anti-mCherry, LifeSpan Biosciences Cat#LS-C204207, 1:1000) Following overnight
5 incubation, the primary antibody was washed away using TBS (x3) and then incubated with secondary antibodies for two hours. For 3, 30-di-aminobenzidine (DAB) immunohistochemistry, biotinylated anti-mouse (Vector Laboratories Cat# BA-2001 RRID:AB_2336180, 1:250), anti-goat (Jackson ImmunoResearch Labs Cat# 705-065-147 RRID:AB_2340397, 1:250) and anti-chicken (Vector Laboratories Cat# BA-9010
10 RRID:AB_2336114, 1:250) secondary antibodies were used. For fluorescence microscopy analysis or biotinylated goat anti chicken (1:250; BA9010, Vector laboratories) was used. For DAB immunohistochemistry, the ABC-kit (Vectorlabs) was used following incubation of the secondary antibody to amplify the staining intensity through streptavidin-peroxidase conjugation and followed by color exposure in 0.01 %
15 H₂O₂.

Immunocytochemistry of primary glial and terminally differentiated neurons

Analysis of vector transduction efficiency in primary glial and neurons differentiated from hESC utilized immunofluorescence detection. First the medium was removed and the cells were washed in 1x PBS. Then 100 µl of 4% PFA was added to each well
20 containing the cells and incubated at 37 degrees for 10 minutes. Following incubation, the cells were washed with PBS. The fixed cell culture was then blocked for one hour in room temperature using 100 µl blocking solution consisting of KPBS with 5% BSA and 0.25 % triton-x per well. The blocking solution was the removed and replaced with primary antibody in PBS and incubated overnight at 4 degrees. Glial cells were
25 identified using the following antibodies: rabbit anti-GFAP (1:1000; ab7260, Abcam) and Rabbit anti-IBA-1 (1:2000; 019-19741, Wako) Following overnight incubation the wells were washed twice with KPBS and then incubated with secondary antibodies in KPBS for a total of two hours in room temperature. Secondary antibodies used
30 included: Alexa conjugated anti-rabbit (Jackson ImmunoResearch Labs Cat# 711-165-152 RRID:AB_2307443, 1:250) Finally the cells were washed twice in KPBS and left in KBPS solution for image analysis.

Laser scanning confocal microscopy

All immunofluorescence analysis was performed using the Leica SP8 microscope. Confocal images were always captured using a HyD detector with the lasers set to be

activated in sequential mode, thus avoiding fluorescence signal bleed through. Solid-state lasers at wavelengths of 405, 488, 552 and 650 nm were utilized to excite the respective fluorophores. The pinhole was always retained at Airy 1 for all image acquisitions. Post acquisition, deconvolution was performed using the “Deconvolution”
5 plugin for ImageJ (developed by the Biomedical Imaging Group [BIG] - EPFL – Switzerland <http://bigwww.ep.ch/>) utilizing the Richardson-Lucy algorithm and applying point-spreads functions (PSFs) calculated for the specific imaging equipment using the Gibson and Lanni model in the PSF Generator (BIG, EPFL – Switzerland <http://bigwww.ep.ch/algorithms/psfgenerator/>).

10 Results

We then utilized the BRAVE technology to screen for the re-introduction of tropism for HEK293T cells *in vitro* (Figure 2B), lost when the HS binding was mutated in the AAV-MNMnull capsid (Figure 2B’). In the screening of the 4 million uniquely barcoded capsid variants, we found several regions from the 131 included proteins that conferred a
15 significantly improved infectivity over the parent AAV-MNMnull capsid structure (not shown). One peptide from HSV-2 surface protein pUL44 was selected and a first novel capsid was generated named AAV-MNM001 (Figure 2A). This capsid, when used to package CMV-GFP independently, displayed a significantly increased tropism to the HEK293T cells (Figure 2B’). In a second experiment, we used the BRAVE technology
20 to improve the infectivity of primary cortical rat neurons *in vitro*. Both AAV2-WT and the AAV-MNMnull vector display very poor infectivity of primary neurons (Figure 2D-D’) and the AAV-MNM001 displays some improvement (Figure 2D’). Through the BRAVE screen, we identified a number of peptides clustering over a C-terminal region of the HSV-2 pUL1 protein (Figure 2C) which when utilized alone in a novel AAV capsid
25 (AAV-MNM002) improved the infectivity of primary neurons in culture dramatically (Figure 2D’’). After these two proof-of-concept studies, demonstrating the validity of the single-generation BRAVE screening, we established the full scale *in vivo* BRAVE screening for the discovery of novel AAV capsids with improved retrograde transport capacity (not shown). From this screening, we selected 23 peptides from 19 proteins
30 that all were represented by multiple barcodes and found in multiple animals. 23 of the *de novo* AAV capsid structures allowed for higher than or at par with AAV2-WT packaging efficacy (Figure 2F). Using the Hammock hidden Markov model-based clustering of all peptides with a retrograde transport ability, we could determine the putative consensus motif for each of the 23 serotypes, providing a foundation for
35 directed optimization.

Characterization of the AAV-MNM004 capsid for retrograde transport in vivo

In the bioinformatics analysis of the HSV pUL22 protein, a C-terminal region of the protein displayed reproducible transport to all afferent regions; Cortex, Thalamus and Substantia Nigra while not showing the same bias at the injection site in the striatum (Figure 3A). HMM clustering of all peptides displaying these properties revealed two overlapping consensus motifs (Figure 3C). Those were generated into the AAV-MNM004 and AAV-MNM023 capsid structures respectively with both displaying similar transport patterns *in vivo* (not shown) with the AAV-MNM004 capsid showing more potent transport ability and less spread at the injection site. The AAV-MNM004 capsid promoted a retrograde transport to all afferent regions as far back as the medial entorhinal cortex while the parent AAV2-Capsid promoted efficient transduction at the site of injection but resulted in very little retrograde transport of the vector (Figure 3D). While we were finalizing this work, another peptide was published promoting strong retrograde transport when displayed in the same location on the AAV2 capsid surface (AAV2-Retro)⁹. When compared *in vivo*, the AAV-MNM004 capsid displayed very similar retrograde transport properties compared to AAV2 capsid with the retro peptide (Retro) injected in the contralateral striatum of the same animal (not shown). This two-fluorophore bilateral injection approach allowed us to efficiently visualize decussating versus ipsilateral projections from the PFC, the intralaminar nuclei of the thalamus and the basolateral amygdala (BLA).

This example shows that modified capsid having improved properties can be designed by identifying fragments of proteins which when displayed on the capsid confer a desired property to the modified capsid.

Example 3 - Utilization of the BRAVE approach to map and understand the function of proteins involved in Alzheimer's disease, both in vivo and in vitro

The BRAVE approach provides a unique possibility to systematically map protein function *in vivo*. We therefore utilized this approach to display peptides from endogenous proteins involved in Alzheimer's disease; APP and Tau and studied if any peptides from these proteins could promote a retrograde transport of the AAV capsid and thus provide insights into the mechanism underlying the proposed cell-to-cell communication of these proteins in the disease (Figure 4). In the mapping of APP we found two regions that conferred retrograde transports, one in the sAAP N-terminal region and one in the Amyloid beta region (not shown). Interestingly, the sAPP region shared significant sequence homology with a region of the VP1 protein from the

Theiler's murine encephalomyelitis virus (TMEV) which appears to drive its axonal uptake and infectivity (Figure 4A). The functional properties of peptides originating from the microtubule associated protein Tau were even more striking. In this protein, a central region conveyed a very efficient retrograde transport. After deeper
5 characterization, this region consisted of three adjacent conserved motifs with the third motif sharing significant homology with both the VSV-G glycoprotein (well used to pseudotype lenti-viruses to improve neuronal tropism) and the HIV gp120 protein (Figure 4B-C, E). Two novel capsid structures were generated from this region, AAV-MNM009 and AAV-MNM017. Both novel capsids promoted retrograde transport *in vivo*
10 but AAV-MNM017 also displayed additional interesting properties. AAV-MNM017 infected both primary neurons and primary glial cells *in vitro* with very high efficacy. Using this property, we then performed a displacement experiment comparing the AAV-MNM017 to the neurotrophic AAV-MNM002 capsid which is not generated from a Tau-related peptide (not shown). Three groups of primary neuron populations were
15 pre-treated with different recombinant Tau variants (T44, T39 and K18). The T44 variant had no apparent effect on the MNM017 to MNM002 ratio of infectivity while K18 enhanced the infectivity of the MNM017 while the T39 variant efficiently blocked the infectivity compared to AAM-MNM002. This suggests that peptide derived from Tau displayed of the AAV surface is utilizing a receptor on the neurons that also has a
20 binding activity of full length human Tau protein but that the post-translational modification of the Tau may be critical for this function. In the *in vitro* assessment of the 24 *de novo* capsid structures generated (AAV-MNM001-024) we found a subset of them (five) that displayed an improved tropism to primary glial cells *in vitro* (not shown). While most of the infectivity was of GFAP positive astrocytes, a few of them also
25 infected the IBA1 positive microglia. A major hurdle for *de novo* capsid design using animal models has been the lack of predictability with regards to the translation to human cells. The BRAVE approach is expected to improve this through the use of naturally occurring peptides from viruses and proteins with known function in the human brain. In the human primary glia, the AAV-MNM017 retains its excellent tropism
30 (Figure 4D-D").

This example shows that modified viral particles obtained by the methods disclosed herein can be used to study protein function and match functional domains.

Example 4 - Assessment of AAV capsid re-shuffling using BRAVE and generation of capsids infecting DA neurons

A number of successful studies have utilized AAV capsid reshuffling between serotypes to generate novel capsids using directed evolution. We have here utilized
5 BRAVE to study the potential of insertion of peptides from other AAV-serotypes into the AAV2 capsid (Figure 5). Interestingly the insertion of peptides from the same region of AAV1,2 and 8 covering the N587 aa were efficiently inserted into the AAV2 capsid. However, the same region from AAV9 did not confer the same function. Moreover, four additional regions from the N-terminal domain of VP1 (also known to be presented on
10 the AAV capsid surface) could also be efficiently inserted. Three of these domains were conserved between AAV1,6,8 and 9 while the fourth was absent in AAV8. In a final BRAVE screening experiment, we aimed to develop a novel AAV capsid variant with efficient retrograde transport to dopamine neurons of the Substantia Nigra from injections into the Striatal output region. In this screening, we identified two regions of
15 the CAV-2 capsid protein in close proximity (Figure 5 A-B). Interestingly, the first peptide shared significant homology with a third region of the same protein (Figure 5A) while the second peptide (Figure 5B) shared a peptide motif from the lectin soybean agglutinin (SA) which also efficiently transports from the synapse to the soma of neurons and can therefore be used as a retrograde tracer²⁰. The CAV-2 is an often-
20 used viral vector for the targeting of DA neurons from the terminal *in vivo*²¹ and we therefore performed an experiment to confirm if this property was retained in the resulting AAV-MNM008 capsid variant. Using a Cre-inducible AAV genome (CMV-loxP-GFP) injected into the striatum of TH-Cre knock-in rats, we found that the AAV-MNM008 was more efficient in infecting the nigral neurons compared to a AAV2-WT capsid carrying the same genome (not shown). To confirm that this property was not
25 limited to rodent DA neurons, we then performed an experiment in DA-denervated, hemi-parkinsonian, immune compromised rats. These animals first received a DA-rich neuronal transplant generated through the differentiation of Cre-expressing human embryonic stem cells (hESCs). 6 months after the transplantation of the neurons, the AAV-MNM008 vector was injected into the frontal cortex of the animals and was
30 efficiently transported back to the transplanted neurons innervating this region (Figure 5C-C''). Through double fluorescence immunohistochemistry we could then confirm that the majority of these cells were indeed TH-positive and thereby inferred to be DA producing (Figure 5C'-C''). Using the same *in vitro* hESC differentiation protocol we
35 then assessed if the *in vitro* neuronal tropism of the *de novo* capsid variants would be

maintained also on neurons with human origin. Indeed, all variants (AAV-MNM002, 008 and 010) which displayed high tropism on primary rodent neurons also showed much higher tropism than the wild-type AAV-variants (not shown). Of note is that the AAV-MNM004 capsid variant, so efficient *in vivo* was not at all suitable for *in vitro* transduction (not shown). Also of interest was that the AAV-MNM001, BRAVE screened in HEK293T cells of human origin was not efficient on primary rat neurons but were very efficient on human neurons (not shown), suggesting a difference in the receptor expression or structure between rodent and human cells and thus showing the value of screening directly in human cells or in humanized systems *in vivo*.

This example shows that the present methods can be used to improve tropism of viral particles.

Example 5 - Functional dissection of the basolateral amygdala and its involvement in the development of anxiety

Materials and methods

Conditioned place preference test

In order to assess selective DREADD activation of the BLA on conditioned place aversion, a two-chamber box was used where each chamber was separated by a wall with a closed door. Each chamber was made different from the other using visual cues on the walls and tactile sensation on the chamber floors while retaining the same light intensity. All tests were recorded using infrared illuminated CCD cameras and the animal's position recorded using the Stoelting ANY-maze 5.2 software package. On day one the animals were first adapted one of the two chambers for a total of three hours following saline injection, being alternated within the group between the two chambers to control for any chamber bias . This trial is denoted "Control". On day two the animals were placed in the opposite chamber from day one following s.c. injection with CNO (3mg/kg) and left in the chamber for 3 hours. This trial is labeled the "Conditioning" trial. On day three the door separating the chambers was removed and the animal was placed inside the box without any drug administration and recorded for a total of three hours for any apparent preferred chamber conditioning, denoted the "Preference test".

Elevated Plus Maze

To assay anxiety levels following selected activation of the BLA using DREADDs, the Elevated Plus Maze (EPM) was used. All animals paced in the EPM was recorded using Stoelting ANY-maze 5.2 software. The EPM was made out of black Plexiglas and consisted of four arms in the shape of a cross. Two of the arms (opposite of each other) were open i.e., without walls while the remaining two arms were enclosed, i.e., had walls. The animals were injected with CNO (3mg/kg) at one and a half hour prior to the start of the test. At the start of the test the animals were placed in the center of the maze and allowed to freely explore the mazes open and closed arms while being recorded for a total of 5 minutes. The animals time exploring either the open or closed arms were then quantified from the recordings in order to determine the animals' anxiety level.

Results

We utilized the BRAVE generated AAV-MNM004 capsid variant to answer an outstanding question regarding the functional contribution of the afferents from the basolateral amygdala to the dorsal striatum (Figure 6). This was conducted using a retrograde-induced chemogenetics (DREADD) approach. We injected the AAV-MNM004 vector expressing Cre-recombinase in the dorsal striatum and a Cre-inducible (DIO) chemogenetic (DREADD) vector into the basolateral amygdala (BLA) bilaterally into wild-type rats (Figure 6A). After selective induction of activity of the BLA neurons projecting to the dorsal striatum using the DREADD ligand CNO, we found a striking fear and anxiety phenotype here exemplified using the elevated plus maze (EPM) where the animals spent significantly less time on the open arms (Figure 6 B) compared to control animals (where the Cre gene was replaced with GFP). This stands in stark contrast to the believed function of the BLA projections to the ventral striatum promoting positive stimuli. This increases anxiety phenotype was accompanied by significant hypermobility in the open-field arena and a fear phenotype including excessive digging, severe sweating and episodes of freezing (Figure 6 C). After the CNO challenges, the animals were sacrificed and the BLA stained for either the HA-tag (identifying the hM3Dq DREADD expression) or mCherry (visualizing the rM3Ds DREADD) using immunohistochemistry developed into a brown precipitation staining using the DAB-peroxidase reaction (Figure 6 D-E).

This example shows that the modified viral vectors and particles obtainable by the methods disclosed herein can be used to help elucidate complex cellular mechanisms.

Example 6 - Sequence overview

Sequence ID NO:	Name	Sequence
1	AAV-MNM001	TVGPRGNASN AAPS
2	AAV-MNM002	ASSQSKPLAT QPPV
3	AAV-MNM003	NLTEYSLSRV DLGD
4	AAV-MNM003	YPDAVYLHRI DLGP
5	AAV-MNM004	VMSVLLVDTD ATQQ
6	AAV-MNM004	VMSVLLVDTD ATQQQLA
7	AAV-MNM004	VMSVLLVDTD NTQQQIA
8	AAV-MNM005	TDDGVSAPIL PNFH
9	AAV-MNM006	SALLPVGQPS HAPSVHLAAA TQ
10	AAV-MNM007	RTPGDEPAPA
11	AAV-MNM007	RTPGDEPAPA VAAQ
12	AAV-MNM008	FTSPLHKNE TV
13	AAV-MNM008	FAYPLVKNDN HV
14	AAV-MNM008	SFTSPLHKNE NTVS
15	AAV-MNM009	FSKVSAETQA SPPE
16	AAV-MNM010	EDNRGINQKL AFNY
17	AAV-MNM011	GAYVAAN
18	AAV-MNM011	ADTVAAP
19	AAV-MNM011	TGDYVAANET HSGR
20	AAV-MNM012	ADSESGGHIT HSGM
21	AAV-MNM012	ADSESGEHIT HSGM
22	AAV-MNM013	ELFSSPN
23	AAV-MNM013	VLFSSPP
24	AAV-MNM013	GLIQSDQELFSSPN

25	AAV-MNM014	GQTGDSESV DPQP
26	AAV-MNM014	GQTGDTEVP DPQP
27	AAV-MNM015	PAHLVNVSEG ANFT
28	AAV-MNM015	LVNVSEGANF T
29	AAV-MNM016	SALLEDPVGT VAPQI
30	AAV-MNM016	SALLEDPAGT VSSQI
31	AAV-MNM017	SIPGFPAEGS IPLP
32	AAV-MNM018	STLLPPELSD TTNAT
33	AAV-MNM018	STLLPPEVVE TANV
34	AAV-MNM019	EDENGLKVT FFTP
35	AAV-MNM019	VDENGT PKPS SLGR
36	AAV-MNM020	SSTD PATGDV HAMG
37	AAV-MNM020	QSSSTD PATG DVHV
38	AAV-MNM020	QSSSTD PATG DVHA
39	AAV-MNM021	DPGYAETPYA SVSH
40	AAV-MNM022	PGGDVPPAGP GEI
41	AAV-MNM022	PGGEVPPAGP GAI
42	AAV-MNM022	LPGGEVPPAG PGAI
43	AAV-MNM023	QQIAAGPTEG APSV
44	AAV-MNM024	LVDTSGY
45	AAV-MNM024	YVDTSGY
46	AAV-MNM024	FIDISGY
47	AAV-MNM024	NTLVDTSGYN AEVS
48	AAV-MNM025	QVWAVEFDTF
49	AAV-MNM025	QTVAVEFDTF
50	AAV-MNM025	SGDQVWAVEF DTFR

51	AAV-MNM001	ACCGTGGGCCCCCGGGGCAACGCCAGCAACGCCGCC CCCAGC
52	AAV-MNM002	GCCAGCAGCCAGAGCAAGCCCCTGGCCACCCAGCCCC CCGTG
53	AAV-MNM003	AACCTGACCGAGTACAGCCTGAGCCGGGTGGACCTGG GCGAC
54	AAV-MNM003	TACCCCGACGCCGTGTACCTGCACCGGATCGACCTGG GCCCC
55	AAV-MNM004	GTGATGAGCGTGCTGCTGGTGGACACCGACGCCACCC AGCAG
56	AAV-MNM004	GTGATGAGCGTGCTGCTGGTGGACACCGACGCCACCC AGCAGCAGCTGGCC
57	AAV-MNM004	GTGATGAGCGTGCTGCTGGTGGACACCGACAACACCC AGCAGCAGATCGCC
58	AAV-MNM005	ACCGACGACGGCGTGAGCGCCCCCATCCTGCCCAACT TCCAC
59	AAV-MNM006	AGCGCCCTGCTGCCCGTGGGCCAGCCCAGCCACGCC CCCAGCGTGACCTGGCCGCCGCCACCCAG
60	AAV-MNM007	CGGACCCCCGGCGACGAGCCCCGCCCCCGCC
61	AAV-MNM007	CGGACCCCCGGCGACGAGCCCCGCCCCCGCCGTGGCC GCCCAG
62	AAV-MNM008	TTCACCAGCCCCCTGCACAAGAACGAGAACACCGTG
63	AAV-MNM008	TTCGCCTACCCCCTGGTGAAGAACGACAACCACGTG
64	AAV-MNM008	AGCTTCACCAGCCCCCTGCACAAGAACGAGAACACCG TGAGC
65	AAV-MNM009	TTCAGCAAGGTGAGCGCCGAGACCCAGGCCAGCCCC CCGAG
66	AAV-MNM010	GAGGACAACCGGGGCATCAACCAGAAGCTGGCCTTCA ACTAC
67	AAV-MNM011	GGCGCCTACGTGGCCGCCAAC
68	AAV-MNM011	GCCGACACCGTGGCCGCCCCC
69	AAV-MNM011	ACCGGCGACTACGTGGCCGCCAACGAGACCCACAGCG GCCGG
70	AAV-MNM012	GCCGACAGCGAGAGCGGCGGCCACATCACCCACAGC GGCATG
71	AAV-MNM012	GCCGACAGCGAGAGCGGCGAGCACATCACCCACAGC GGCATGGC
72	AAV-MNM013	GAGCTGTTCAGCAGCCCCAAC
73	AAV-MNM013	GTGCTGTTCAGCAGCCCCCCCGC
74	AAV-MNM013	GGCCTGATCCAGAGCGACCAGGAGCTGTTCAGCAGCC CCAAC
75	AAV-MNM014	GGCCAGACCGGCGACAGCGAGAGCGTGCCCGACCCC CAGCCC
76	AAV-MNM014	GGCCAGACCGGCGACACCGAGAGCGTGCCCGACCCC CAGCCC

77	AAV-MNM015	CCCGCCACCTGGTGAACGTGAGCGAGGGCGCCAACCTCACC
78	AAV-MNM015	CTGGTGAACGTGAGCGAGGGCGCCAACCTTCACC
79	AAV-MNM016	AGCGCCCTGCTGGAGGACCCCGTGGGCACCGTGGCC CCCCAG ATC
80	AAV-MNM016	AGCGCCCTGCTGGAGGACCCCGCCGGCACCGTGGAGC AGCCAGATC
81	AAV-MNM017	AGCATCCCCGGCTTCCCCGCCGAGGGCAGCATCCCC TGCC
82	AAV-MNM018	AGCACCTGCTGCCCCCGAGCTGAGCGACACCACCA ACGCCACC
83	AAV-MNM018	AGCACCTGCTGCCCCCGAGGTGGTGGAGACCGCCA ACGTG
84	AAV-MNM019	GAGGACGAGAACGGCACCCCTGAAGGTGACCTTCCCCA CCCC
85	AAV-MNM019	GTGGACGAGAACGGCACCCCAAGCCAGCAGCCTGG GCCGG
86	AAV-MNM020	AGCAGCACCGACCCCGCCACCGGCGACGTGCACGCC ATGGGC
87	AAV-MNM020	CAGAGCAGCAGCACCGACCCCGCCACCGGCGACGTG CACGTG
88	AAV-MNM020	CAGAGCAGCAGCACCGACCCCGCCACCGGCGACGTG CACGCC
89	AAV-MNM021	GACCCCGGCTACGCCGAGACCCCTACGCCAGCGTGA GCCAC
90	AAV-MNM022	CCCGGCGGCGACGTGCCCGCCGGCCCCGGCGAG ATC
91	AAV-MNM022	CCCGGCGGCGAGGTGCCCGCCGGCCCCGGCGCC ATC
92	AAV-MNM022	CTGCCCGGCGGCGAGGTGCCCGCCGGCCCCGGC GCCATC
93	AAV-MNM023	CAGCAGATCGCCGCCGCCACCGAGGGCGCCCC AGCGTG
94	AAV-MNM024	CTGGTGGACACCAGCGGCTAC
95	AAV-MNM024	TACGTGGACACCAGCGGCTAC
96	AAV-MNM024	TTCATCGACATCAGCGGCTAC
97	AAV-MNM024	AACACCCTGGTGGACACCAGCGGCTACAACGCCGAGG TGAGC
98	AAV-MNM025	CAGGTGGTGGCCGTGGAGTTCGACACCTTC
99	AAV-MNM025	CTGACAAGACCACCCAGACCGTGGCCGTGGAGTTCGA CACCTTCG
100	AAV-MNM025	AGCGGCGACCGAGGTGGTGGCCGTGGAGTTCGACACCT TCCGG
101	AAV2 VP1	MAADGYLPDWLEDLSEGIQWWKLPKPPPKPAERH KDDSRGLVLPKYKYLGPFNGLDKGEPVNEADAAALEHDK AYDRQLDSGDNYPYLKYNHADADEFQERLKEDTSFGGNLG RAVFQAKKRVLEPLGLVEEPVKTAPGKKRPVEHSPVEPD

	SSSGTGKAGQQPARKRLNFGQTGDADSVDPQPPLGQPP AAPSGGLGTNTMATGSGAPMADNNEGADGVGNSSGNWH CDSTWMGDRVITTSTRTWALPTYNNHLYKQISSQSGASN DNHYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGF RPKRLNFKLFNIQVKEVTQNDGTTTIANNLTSTVQVFTDSE YQLPYVLGSAHQGCLPPFPADVFMVPQYGYLTLNNGSQA VGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPPHSSYA HSQSLDRLMNPLIDQYLYLSRTNTPSGTTTQSRLQFSQA GASDIRDQSRNWLPGPCYRQQRVSKTSADNNNSEYSWT GATKYHLNGRDSLVPNPGPAMASHKDDEEKFFPQSGVLIF GKQGSEKTNVDIEKVMITDEEEIRTTNPVATEQYGSVSTN LQRGNRQAATADVNTQGVLPGMVWQDRDVYLQGPWAK IPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPSTTF SAAKFASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYT SNYNKSVNVDFTVDTNGVYSEPRPIGTRYLTRNL
--	---

References

1. Gray, S.J. et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). *Mol Ther* **18**, 570-578 (2010).
2. Chan, K.Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. *Nat Neurosci* **20**, 1172-1179 (2017).
3. Deverman, B.E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. *Nat Biotechnol* **34**, 204-209 (2016).
4. Ojala, D.S. et al. In Vivo Selection of a Computationally Designed SCHEMA AAV Library Yields a Novel Variant for Infection of Adult Neural Stem Cells in the SVZ. *Mol Ther* (2017).
5. Grimm, D. et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. *J Virol* **82**, 5887-5911 (2008).
6. Maheshri, N., Koerber, J.T., Kaspar, B.K. & Schaffer, D.V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. *Nat Biotechnol* **24**, 198-204 (2006).
7. Muller, O.J. et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. *Nat Biotechnol* **21**, 1040-1046 (2003).

8. Yang, L. et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. *Proc Natl Acad Sci U S A* **106**, 3946-3951 (2009).
- 5 9. Tervo, D.G. et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. *Neuron* **92**, 372-382 (2016).
10. Adachi, K., Enoki, T., Kawano, Y., Veraz, M. & Nakai, H. Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing. *Nat Commun* **5**, 3075 (2014).
- 10 11. Girod, A. et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. *Nat Med* **5**, 1052-1056 (1999).
12. Opie, S.R., Warrington, K.H., Jr., Agbandje-McKenna, M., Zolotukhin, S. & Muzyczka, N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. *J Virol* **77**, 6995-7006 (2003).
- 15 13. Perabo, L. et al. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. *J Virol* **80**, 7265-7269 (2006).
- 20 14. Ried, M.U., Girod, A., Leike, K., Buning, H. & Hallek, M. Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. *J Virol* **76**, 4559-4566 (2002).
15. McCarty, D.M. et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. *Gene Ther* **10**, 2112-2118 (2003).
- 25 16. McCarty, D.M., Monahan, P.E. & Samulski, R.J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. *Gene Ther* **8**, 1248-1254 (2001).
- 30 17. Davidsson, M. et al. A novel process of viral vector barcoding and library preparation enables high-diversity library generation and recombination-free paired-end sequencing. *Sci Rep* **6**, 37563 (2016).

18. Streck, C.J. et al. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models. *Clin Cancer Res* **11**, 6020-6029 (2005).
19. Jordan, M., Schallhorn, A. & Wurm, F.M. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. *Nucleic Acids Res* **24**, 596-601 (1996).
20. Shortland, P.J., Wang, H.F. & Molander, C. Transganglionic transport of the lectin soybean agglutinin (Glycine max) following injection into the sciatic nerve of the adult rat. *J Neurocytol* **27**, 233-245 (1998).
21. Hnasko, T.S. et al. Cre recombinase-mediated restoration of nigrostriatal dopamine in dopamine-deficient mice reverses hypophagia and bradykinesia. *Proc Natl Acad Sci U S A* **103**, 8858-8863 (2006).
22. Stahl, P.L. et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. *Science* **353**, 78-82 (2016).
23. Yan, Z. et al. A novel chimeric adenoassociated virus 2/human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia. *Mol Ther* **21**, 2181-2194 (2013).
24. Gray, J.T. & Zolotukhin, S. Design and construction of functional AAV vectors. *Methods Mol Biol* **807**, 25-46 (2011).
25. Grimm, D., Kern, A., Rittner, K. & Kleinschmidt, J.A. Novel tools for production and purification of recombinant adenoassociated virus vectors. *Hum Gene Ther* **9**, 2745-2760 (1998).
26. Ho, S.N., Hunt, H.D., Horton, R.M., Pullen, J.K. & Pease, L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Gene* **77**, 51-59 (1989).
27. Michelfelder, S. & Trepel, M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. *Adv Genet* **67**, 29-60 (2009).
28. Chen, X., Zaro, J.L. & Shen, W.C. Fusion protein linkers: property, design and functionality. *Adv Drug Deliv Rev* **65**, 1357-1369 (2013).
29. Reddy Chichili, V.P., Kumar, V. & Sivaraman, J. Linkers in the structural biology of protein-protein interactions. *Protein Sci* **22**, 153-167 (2013).

30. Williams, R. et al. Amplification of complex gene libraries by emulsion PCR. *Nature methods* **3**, 545-550 (2006).
31. Zolotukhin, S. et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. *Gene Ther* **6**, 973-985 (1999).
- 5 32. Rohr, U.P. et al. Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. *J Virol Methods* **106**, 81-88 (2002).
- 10 33. Gray, S.J. et al. Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration. *Curr Protoc Neurosci* **Chapter 4**, Unit 4 17 (2011).
34. Wu, X., Dong, X., Wu, Z. et al A novel method for purification of recombinant adenoassociated virus vectors on a large scale. *Chinese Science Bulletin* **46**, 485-488 (2001).
- 15 35. Brewer, G.J. & Torricelli, J.R. Isolation and culture of adult neurons and neurospheres. *Nat Protoc* **2**, 1490-1498 (2007).
36. Nolbrant, S., Heuer, A., Parmar, M. & Kirkeby, A. Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. *Nat Protoc* **12**, 1962-1979 (2017).
- 20 37. Zorita, E., Cusco, P. & Fillion, G.J. Starcode: sequence clustering based on all-pairs search. *Bioinformatics* **31**, 1913-1919 (2015).
38. Krejci, A., Hupp, T.R., Lexa, M., Vojtesek, B. & Muller, P. Hammock: a hidden Markov model-based peptide clustering algorithm to identify protein-interaction consensus motifs in large datasets. *Bioinformatics* **32**, 9-16 (2016).
- 25 39. Bushnell, B. (Berkeley, California; 2016).
40. Dean, J. & Ghemawat, S. MapReduce: simplified data processing on large clusters. *Communications of the ACM* **51**, 107-113 (2008).
41. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome research* **20**, 1297-1303 (2010).
- 30 42. Edgar, R.C. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* **26**, 2460-2461 (2010).

Items

1. A method of manufacturing a library of viral vectors, said method comprising:
 - 5 i) selecting one or more candidate polypeptides from a group of polypeptides having or suspected of having a desired property, and retrieving the sequences of said polypeptides;
 - ii) providing a plurality of candidate polynucleotides, each candidate
10 polynucleotide encoding a polypeptide fragment of one of said candidate polypeptides, such that upon transcription and translation each candidate polypeptide is represented by one or more polypeptide fragments of each candidate polypeptide;
 - iii) providing a plurality of barcode polynucleotides;
 - iv) inserting each candidate polynucleotide together with a barcode
15 polynucleotide into a viral vector, comprising a capsid gene and a viral genome, thereby obtaining a plurality of viral vectors each comprising a single candidate polynucleotide operably linked to a barcode polynucleotide, wherein the candidate polynucleotide is inserted within the capsid gene, the capsid gene is outside the viral genome and the barcode polynucleotide is
20 inserted within the viral genome; wherein the viral vector comprises a marker polynucleotide encoding a detectable marker;
 - v) amplifying the plurality of viral vectors obtained in step iv) in an amplification system, wherein each viral vector is present in a plurality of copies in the amplification system; and
 - 25 a) retrieving and transferring at least a first part of the plurality of viral vectors from the amplification system of step v) in a reference system, thereby mapping each barcode polynucleotide to one candidate polynucleotide; and
 - b) maintaining a second part of the plurality of viral vectors in the amplification system, and optionally transferring all or part of said second part in a production
30 system to obtain a plurality of viral particles.
2. The method of item 1, wherein the one or more polypeptide fragment is at least two overlapping polypeptide fragments.

3. The method of any one of the preceding items, wherein the viral vector is a plasmid.
4. The method of any one of the preceding items, wherein mapping each barcode polynucleotide to one candidate polynucleotide is done by sequencing a region of each viral vector of the plurality of viral vectors, said region comprising at least the barcode polynucleotide and the candidate polynucleotide.
5. The method of any one of the preceding items, wherein the sequencing is performed by next generation sequencing, such as Illumina sequencing of the region.
6. A method of designing a viral vector having a desired property, comprising the method of any one of items 1 to 5 and further comprising the steps of:
 - vi) retrieving a fraction of viral vectors from the amplification system of step v) b) of item 1, or retrieving at least part of the viral particles from the production system of step v) b) of item 1, and contacting a cell population with said retrieved viral vectors or viral particles;
 - vii) monitoring marker expression and selecting the cells wherein marker expression follows a desired pattern;
 - viii) identifying the barcode polynucleotides expressed in the cells selected in step vii), thereby identifying the candidate polynucleotides responsible for the desired property and the corresponding candidate polypeptides;
 - ix) designing a viral vector comprising a modified capsid gene, wherein the modified capsid gene comprises one of the candidate polynucleotides identified in step viii).
7. The method of item 6, further comprising the step of amplifying the viral vector obtained in step ix) in an amplification system.
8. A method of manufacturing a viral particle having a desired property, said method comprising the method of any one of items 1 to 5 and further comprising the steps of:
 - vi) retrieving at least part of the plurality of viral vectors from the amplification system of step v) b) or retrieving at least part of the plurality of viral particles from the production system of step v) b);

- vii) contacting a cell population with the retrieved viral vectors or viral particles obtained in step vi);
- viii) monitoring marker expression and selecting the cells wherein marker expression follows a desired pattern;
- 5 ix) identifying the barcode polynucleotides expressed in the cells identified in step viii), thereby identifying the candidate polynucleotides responsible for the desired property and the corresponding candidate polypeptides;
- x) designing a viral vector comprising a modified capsid gene, wherein the modified capsid gene comprises one of the candidate polynucleotides identified in step ix);
- 10 xi) producing the viral vector of step x) in a production system, thereby obtaining the viral vector or the viral particle having the desired property.
9. A method of delivering a transgene to a target cell, said method comprising:
- 15 a) providing a modified viral vector or a modified viral particle comprising a modified capsid and encapsulating a transgene, wherein the modified viral vector or the modified viral particle is the viral vector or the viral particle defined in step xi) of item 8; and
- b) injecting said modified viral vector or said modified viral particle into an
- 20 injection site.
10. The method according to item 9, wherein the modified viral particle comprises a modified capsid comprising or consisting of a polypeptide which comprises or consists of a variant of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID
- 25 NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID
- 30 NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or of SEQ ID NO: 50, wherein
- 35 at the most one, two or three amino acid residues have been deleted, modified or replaced.

11. A library of viral vectors, each viral vector comprising:
- i) a backbone for expressing the viral vector in a host cell;
 - 5 ii) a capsid gene and a candidate polynucleotide inserted therein, said candidate polynucleotide encoding a polypeptide fragment of a candidate polypeptide;
 - iii) a marker polynucleotide; and
 - iv) a barcode polynucleotide;
- 10 wherein
- the candidate polypeptide is selected from a predefined group comprising one or more polypeptides having or suspected to have a desired property;
- wherein upon transcription and translation each candidate polypeptide is represented by one or more polypeptide fragments in the library;
- 15 the candidate polynucleotide is inserted within the capsid gene of the viral vector so that it can be transcribed and translated to a polypeptide fragment displayed on the capsid, and is operably linked to a barcode polynucleotide inserted within the viral genome,
- and the marker polynucleotide is comprised within the viral genome and the capsid
- 20 gene is outside the viral genome.
12. The library of viral vectors according to any one of the preceding items, wherein the one or more polypeptide fragments is at least two overlapping polypeptide fragments.
- 25
13. The library of viral vectors according to any one of the preceding items, wherein the marker polynucleotide is the barcode polynucleotide.
14. The library of viral vectors according to any one of the preceding items, wherein
- 30 the viral vector is an adeno-associated virus (AAV), a retrovirus, a lentivirus, an adeno-virus, a herpes simplex virus, a bocavirus or a rabies virus, preferably an adeno-associated virus (AAV).
15. The library of viral vectors according to any one of the preceding items, wherein
- 35 the viral vector further comprises at least one replication gene.

16. The library of viral vectors according to any one of the preceding items, wherein the viral vector further comprises at least one assembly gene.
17. The library of viral vectors according to any one of the preceding items, wherein
5 the candidate polynucleotide is located between the 5'-end of the capsid gene and the 3'-terminal-end of the capsid gene.
18. The library of viral vectors according to any one of the preceding items, wherein
10 the marker polypeptide is selected from the group consisting of: a fluorescent protein, a bioluminescent protein, an antibiotic resistance gene, a cytotoxic gene, a surface receptor, β -galactosidase, the TVA receptor, pro-mitotic/oncogenes, trans-activators, transcription factors and Cas proteins.
19. The library of viral vectors according to any one of the preceding items, wherein
15 the marker polynucleotide further comprises a promoter sequence.
20. The library of viral vectors according to any one of the preceding items, wherein the promoter is a constitutive promoter or an inducible promoter.
21. The library of viral vectors according to any one of the preceding items, wherein
20 the promoter is a phosphoglycerate kinase (PGK), chicken beta actin (CBA), cytomegalovirus (CMV) early enhancer/chicken β actin (CAG), hybrid CBA (CBh), neuron-specific enolase (NSE), tyrosine hydroxylase (TH), tryptophan hydroxylase (TPH), platelet-derived growth factor (PDGF), aldehyde
25 dehydrogenase 1 family member L1 (ALDH1L1), synapsin-1, cytomegalovirus (CMV), histone 1 (H1), U6 spliceosomal RNA (U6), calmodulin-dependent protein kinase II (CamKII), elongation factor 1-alpha (Ef1a), forkhead box J1 (FoxJ1), or glial fibrillary acidic protein (GFAP) promoter.
22. The library of viral vectors according to any one of the preceding items, wherein
30 the barcode polynucleotide is located at the 3' untranslated region (3'-UTR) of the marker polynucleotide.
23. The library of viral vectors according to any one of the preceding items, wherein
35 the host cell is a mammalian cell, such as a human cell, an insect cell such as an SF9 cell or a yeast cell such as a *Saccharomyces cerevisiae* cell.

24. The library of viral vectors according to any one of the preceding items, wherein the host cell is a Hela cell, a primary neuron, an induced neuron, a fibroblast, an embryonic stem cell, an induced pluripotent stem cell, an insect cell such as an SF9 cell, a yeast cell or an embryonic cell, such as an embryonic kidney cell, for example HEK293 cells.
25. The library of viral vectors according to any one of the preceding items, wherein the candidate polypeptides are selected from: viral polypeptides such as a capsid polypeptide or an envelope polypeptide; polypeptides related to a disease or a disorder; polypeptides sharing a common function; neurotoxins and lectins.
26. The library of viral vectors according to any one of the preceding items, wherein the candidate polypeptides are polypeptides known to have or suspected of having a desired property.
27. The library of viral vectors according to any one of the preceding items, wherein the desired property is one or more of:
- affinity to a given cellular structure, such as a structure specific to a given type of cells, such as a synapse, or to a structure specific to a given cellular event, such as cellular division, cell differentiation, neuronal activation, inflammation or tissue damage;
 - improved transport properties, such as improved transport in the environment surrounding a host cell or improved transport across the blood-brain barrier;
 - increased ability to escape metabolism liver;
 - increased ability to evade the immune system;
 - increased ability to trigger the immune system.
28. The library of viral vectors according to any one of the preceding items, wherein the candidate polynucleotide, the marker polynucleotide and/or the barcode polynucleotide is codon-optimised.
29. A cell or a plurality of cells, comprising the library of viral vectors according to any one of items 11 to 28.

30. A viral vector encoding a viral particle for delivery of a transgene to a target cell, said viral vector comprising a modified capsid gene and a transgene to be delivered to the target cell;

wherein

5 the modified capsid gene is outside the viral genome and comprises or consists of a polynucleotide encoding a polypeptide improving delivery of the transgene and/or targeting to the target cell.

10 31. The viral vector according to item 30, wherein the viral vector is an adeno-associated virus (AAV), a retrovirus, a lentivirus, an adeno-virus, a herpes simplex virus, a bocavirus or a rabies virus.

15 32. The viral vector according to any one of items 30 to 31, wherein the polypeptide comprises or consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or of SEQ ID NO: 50.

25 33. The viral vector according to any one of items 30 to 32, wherein the polypeptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45,

SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or of SEQ ID NO: 50.

5 34. The viral vector according to any one of items 30 to 33, wherein the transgene is inserted between the terminal repeat (TR) sequences of the viral genome.

35. The viral vector according to any one of items 30 to 34, wherein the viral vector upon injection to an injection site promotes retrograde transport to regions afferent to the injection site.

10

36. A viral particle encoded by the viral vector according to any one of items 30 to 35.

15 37. A modified viral vector or viral particle for delivery of a transgene to a target cell, said modified viral vector or viral particle comprising a modified capsid and a transgene to be delivered to the target cell;

wherein

20 the modified capsid improves one or more of: delivery of the transgene to the target cell, targeting to the target cell, infectivity of the modified viral vector or modified viral particle, and/or retrograde transport of the modified viral vector or modified viral particle compared to an unmodified viral particle comprising a native capsid gene and the transgene.

25 38. The modified viral vector or the modified viral particle according to item 37, wherein the modified capsid comprises or consists of a polypeptide comprising or consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or of SEQ ID NO: 50 .

30

35

39. The modified viral vector or the modified viral particle according to any one of items 37 to 38, wherein the peptide is displayed on the modified capsid.
- 5 40. Use of a viral vector or a viral particle according to any one of items 30 to 36, or of a modified viral vector or a modified viral particle according to any one of items 37 to 40, for gene therapy.
- 10 41. A viral vector or a viral particle according to any one of items 30 to 35, or a modified viral vector or a modified viral particle according to any one of items 36 to 40, for use in a method of treatment of a disorder, such as a disorder of the nervous system.
- 15 42. The viral vector or particle or the modified viral vector or particle for the use according to item 41, wherein the disorder is selected from the group consisting of: enzyme deficiency, metabolic disorders, aggregopathy, oncogenicity, neuronal hyper- or hypo-activity, protein dysregulation and erroneous gene splicing.
- 20 43. The viral vector or particle or the modified viral vector or particle for the use according to any one of items 41 to 41, wherein the disorder is selected from the group consisting of Huntington's disease, cerebellar ataxia, multiple system atrophy, depression, epilepsy, amyotrophic lateral sclerosis, stroke, haemophilia, spinal muscular atrophy, muscular dystrophy.
- 25 44. A method for identifying a drug having a desired effect, said method comprising the steps of:
- 30 a) Providing a candidate drug;
- b) Administering the candidate drug to a cell;
- 30 c) Providing a modified viral particle comprising a modified capsid allowing delivery of the viral particle to the cell of b) and a marker polynucleotide;
- d) Monitoring and comparing expression and/or localisation of the marker polypeptide in the presence and absence of the candidate drug; thereby determining whether the candidate drug has an effect on the
- 35 expression of the marker polynucleotide

wherein the modified viral particle and/or the modified capsid are as defined in any one of the preceding items.

- 5 45. A method for improving tropism of a viral vector or particle toward a target cell, said method comprising the method of any one of items 1 to 5, and further comprising the steps of:
- vi) retrieving at least part of the plurality of viral vectors from the amplification system of step v) b) or retrieving at least part of the plurality of viral particles from the production system of step v) b);
 - 10 vii) contacting a cell population comprising target cells with the retrieved viral vectors or viral particles obtained in vi) and with a reference viral vector or a reference viral particle comprising a marker;
 - viii) monitoring and comparing marker expression in the target cells;
 - 15 ix) identifying the candidate polynucleotides in the target cells having increased expression of the marker compared to the expression from the reference viral vector or reference viral particle;
 - x) designing a viral vector or a viral particle with improved tropism, comprising a modified capsid gene, wherein the modified capsid gene comprises one of the candidate polynucleotides identified in step ix).
- 20
46. A method of identifying one or more regions of a polypeptide conferring a desired property to a viral particle comprising a capsid modified by insertion of said polypeptide therein, said method comprising the method of any one of items 1 to 5, and further comprising the steps of:
- 25 vi) retrieving at least part of the plurality of viral vectors from the amplification system of step v) b) or retrieving at least part of the plurality of viral particles from the production system of step v) b);
 - vii) contacting a cell population comprising target cells with the retrieved viral vectors or viral particles obtained in vi) and with a reference viral vector or a reference viral particle comprising a marker;
 - 30 viii) monitoring and comparing marker expression in the target cells;
 - ix) identifying the candidate polynucleotides in the target cells having an expression profile of the marker corresponding to the desired property, thereby identifying the region of the polypeptide responsible for said
 - 35 property.

Claims

1. A viral vector encoding a viral particle for delivery of a transgene to a target cell, said viral vector comprising a modified capsid gene and a transgene to be delivered to the target cell;
5 wherein the modified capsid gene is outside the viral genome and comprises a polynucleotide encoding a polypeptide improving delivery of the transgene and/or targeting to the target cell, and
10 wherein the polypeptide comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 3 to 24, SEQ ID NO: 27 to 35 and SEQ ID NO: 39 to 50,
wherein up to three amino acid residues have been deleted, modified or replaced.
- 15 2. A modified viral particle for delivery of a transgene to a target cell, said modified particle comprising a modified capsid and a transgene to be delivered to a host cell;
wherein the modified capsid improves one or more of: delivery of the transgene to the target cell, targeting to the target cell, infectivity of the viral particle,
20 and/or retrograde transport of the modified viral particle compared to an unmodified viral particle comprising a native capsid gene and the transgene, and the modified capsid gene is outside the viral genome, and
wherein the modified capsid comprises a polypeptide selected from the group consisting of SEQ ID NO: 3 to 24, SEQ ID NO: 27 to 35 and to SEQ ID NO: 39
25 to 50,
wherein up to three amino acid residues have been deleted, modified or replaced.
- 30 3. The viral vector or the modified viral particle according to any one of the preceding claims, wherein the polypeptide is encoded by a polynucleotide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 53 to 74, SEQ ID NO: 77 to 85 and SEQ ID NO: 89 to 100.
- 35 4. The viral vector according to any one of claims 1 or 3, wherein the viral vector is an adeno-associated virus (AAV), a retrovirus, a lentivirus, an adeno-virus, a

herpes simplex virus, a bocavirus or a rabies virus, preferably an adeno-associated virus (AAV).

- 5
5. The modified viral particle according to any one of claims 2 or 3, wherein the modified viral particle is derived from an adeno-associated virus (AAV), a retrovirus, a lentivirus, an adeno-virus, a herpes simplex virus, a bocavirus or a rabies virus, preferably an adeno-associated virus (AAV).
- 10
6. The viral vector according to any one of claims 1, 3 or 4, further comprising at least one replication gene and/or at least one assembly gene.
- 15
7. The viral vector according to any one of claims 1, 3, 4, or 6, wherein the transgene is inserted between the terminal repeat (TR) sequences of the viral genome.
- 20
8. The viral vector according to any one of claims 1, 3, 4, 6 or 7, wherein the viral vector upon injection to an injection site promotes retrograde transport to regions afferent to the injection site.
- 25
9. The viral vector or the modified viral particle according to any one of the preceding claims, wherein the transgene upon expression in the target cell results in knock-down or correction of genes causing Parkinson's disease, such as alpha-synuclein (SNCA), LRRK2, Pink1, PRKN, GBA, DJ1, UCHL1, MAPT, ATP13A2 or VPS35.
- 30
10. The viral vector or the modified viral particle according to any one of the preceding claims, wherein the target cell is a neuron, such as a cortical neuron, a neuron of the hippocampus, of the entorhinal cortex, of the cerebellum, of the spinal cord, at the epileptic focus, of the nucleus accumbens, or of the Habenula; a glial cell, such as a glial cell of the caudate-putamen, of the substantia nigra, of the cerebral cortex, of the infarct area; a DA neuron, such as of the substantia nigra or of the ventral tegmental area; or a muscle myocyte.

11. A method of treatment or prophylaxis of a disease or disorder, said method comprising the step of administering a viral vector or the modified viral particle according to any one of the preceding claims to a subject in need thereof.
- 5 12. The method according to claim 11, wherein the disorder is selected from the group consisting of: Parkinson's disease, Alzheimer's disease, schizophrenia, enzyme deficiency, metabolic disorders, aggregopathy, oncogenicity, neuronal hyper- or hypo-activity, protein dysregulation, erroneous gene splicing, Huntington's disease, cerebellar ataxia, multiple system atrophy, depression, 10 epilepsy, amyotrophic lateral sclerosis, stroke, haemophilia, spinal muscular atrophy and muscular dystrophy.
13. A method for identifying a drug having a desired effect, said method comprising the steps of:
- 15 a. Providing a candidate drug;
- b. Administering the candidate drug to a cell;
- c. Providing a modified viral particle according to any one of claims 2, 3, 5, 9 or 10 comprising a modified capsid allowing delivery of the viral particle to the cell of b) and a marker polynucleotide;
- 20 d. Monitoring and comparing expression and/or localisation of the marker polypeptide in the presence and absence of the candidate drug; thereby determining whether the candidate drug has an effect on the expression of the marker polynucleotide.
- 25 14. A method of delivering a transgene to a target cell, said method comprising:
- a. providing a modified viral vector or a modified viral particle comprising a modified capsid and encapsulating a transgene, wherein the modified viral vector or the modified viral particle is the viral vector or the viral particle according to any one of claims 1 to 10; and
- 30 b. injecting said modified viral vector or said modified viral particle into an injection site.
15. Use of a viral vector or a modified viral particle according to any one of claims 1 to 10 in the preparation of a medicament for the treatment or prophylaxis of a 35 disease or disorder.

- 5
16. The use according to claim 15 wherein the disease or disorder is selected from the group consisting of: Parkinson's disease, Alzheimer's disease, schizophrenia, enzyme deficiency, metabolic disorders, aggregopathy, oncogenicity, neuronal hyper- or hypo-activity, protein dysregulation, erroneous gene splicing, Huntington's disease, cerebellar ataxia, multiple system atrophy, depression, epilepsy, amyotrophic lateral sclerosis, stroke, haemophilia, spinal muscular atrophy and muscular dystrophy.

FIG.1




FIG.1 (CONT.)

B 1. NCBI AA Reference Sequence

```


5' ... ATGAAGTTATGGGATGTCGTGGCTGTCTGCCTGGTGTGCTCCACACCGCGTCTGCCTTCCCG ... 3'
M K L W D V V A V C L V L L H T A S A F P
+1 K L W D V V A V C L V L L H
+1 L W D V V A V C L V L L H T
+1 W D V V A V C L V L L H T A
+1 D V V A V C L V L L H T A S
+1 V V A V C L V L L H T A S A
+1 V A V C L V L L H T A S A F
    
```

2. Addition of linkers and Codon optimization


```

18bp N-Cap G G G G G S V A V C L V L L H T A S A F G G G G G S 18bp C-Cap
5' ... GGAGGCGGC GGAAGCGTGGCTGTCTGCCTGGTGTGCTCCACACCGCGTCTGCCTTCCGAGGCGGC GGAAGC ... 3'
    
```


3. CustomArray oligonucleotide array synthesis




4. Gibson assembly into barcoded AAV plasmid




5a. *In vitro* Cre-recombination and NGS LUT generation



5b. *In vitro* and *in vivo* assays with mRNA BC sequencing



6. Mapping of functional domains to reference sequences



7. HMM clustering of consensus motifs using Hammock



FIG. 1 (CONT.)




FIG. 2




FIG. 2 (CONT.)





FIG. 3



B

Alignment	Ctx	Th	SN
----VMSVLLVDTDATQQ-----	■	■	■
-----MVDTDATQQQLAQG--	■	■	■
-----VDTDATQQQLAQQP-	■	■	■
PAGEVMSVLLVDTDNTQQQIAA---	■	■	■
-----SVLLVDTDNTQQQI-----	■	■	■
-----VDTDNTQQQIAAGP-	■	□	■
-----MVDTDNTQQQIAAG--	□	■	□
---EVMSVLLVDTDATQ-----	□	■	■
PAGEVMSVLLVDTDATQQQLAQ---	■	□	□
---EVMSVLLVDTDATQQQLAQQPV	□	■	□

FIG. 3 (CONT.)

C

Ctx	Th	SN	Alignment
			-QQIAAGPTEGAPSV-----
			--QIAAGPTEGAPSVF-----
			-----EGAPSVFSSDVPST
			-----TEGAPSVFSSDVPS-
			QQQIAAGPTEGAPS-----

D




FIG. 4

A

Alignment	Ctx	Th	SN	
-----TTSEPLPQDPVKLPTTAASTPD				APP [aa 352-373]
-----TTSEPLPQDPVKLP-----				APP [aa 352-365]
SQSLLKTTSEPLPQDPVKLPTT-----				APP [aa 346-367]
-----TSEPLPQDPVKLPT-----				APP [aa 353-366]
-----QDPVKLPTTAASTP-				APP [aa 359-372]
-----DASVDFVAEPVKLP-----				TMEV-VP1 [aa 14-27]
-----SVDFVAEPVKLPEN-----				TMEV-VP1 [aa 16-29]

B

Ctx	Th	SN

C

Alignment	Ctx	Th	SN
-----SIPGFPAEGSIPLP-			
-----IPGFPAEGSIPLPA--FSKVSAETQASPPE-----			
---TTSIPGFPAEGSIP--ADFFSKVSAETQAS-----			
SGETTSSIPGFPAEG-----ADFFSKVSAETQASPPEGPGTG-			
-----ETQASPPEGPGTGP			

FIG. 4 (CONT.)






FIG. 4 (CONT.)

		Alignment	Ctx	Th	SN
E	Tau [aa 275-288]	-TQASPPEGPGTGPS-----	■	■	
	Tau [aa 276-289]	--QASPPEGPGTGPSE-----	■	■	
	Tau [aa 280-293]	-----PEGPGTGPSEEGHE		■	
	Tau [aa 274-287]	ETQASPPEGPGTGP-----		■	
	VSV-G [aa 322-335]	-----APKNPGTGPAFTII-	■		■
	VSV-G [aa 319-332]	--SYLAPKNPGTGPVF-----	■		
	VSV-G [aa 320-333]	---YLAPKNPGTGPVFT---		■	
	VSV-G [aa 318-331]	-LSYLAPKNPGTGPA-----	■		
	HIV-gp120 [aa 202-215]	---CNDKNFNGTGPKN---	■	■	■

FIG. 5

A

	Alignment	Ctx	Th	SN
CAV-2 [aa 101-114]	- - - SFTSPLHKNENTVS -			
CAV-2 [aa 100-113]	- - LSFTSPLHKNENTV - -			
CAV-2 [aa 281-294]	- - - TFAYPLVKNDNHVA -			

B

	Alignment	Ctx	Th	SN
CAV-2 [aa 122-135]	- - - EDENGLTKVTFPTP -			
CAV-2 [aa 120-133]	- GLEDENGLTKVTFP - - -			
SA [aa 37-50]	- - - VDENGTPKPSSLGR -			
SA [aa 35-48]	- NKVDENGTPKPSSL - - -			
SA [aa 34-47]	LNKVDENGTPKPSS - - - -			
SA [aa 38-51]	- - - - DENGTPKPSSLGRA			







FIG. 6




FIG. 6 (CONT.)




FIG. 6 (CONT.)








FIG. 7

A



B



C











FIG. 8



Legend

-  loxP site 1
-  loxP site 2
-  BC molecular barcode
-  SPBS sequencing primer binding site
-  spA synthetic (unidirectional) poly-adenylation site
-  barcode amplification primers

eolf-othd-000002 (28).txt
SEQUENCE LISTING

<110> Björklund, Tomas
Davidsson, Marcus

<120> Modified capsids with improved properties

<130> P4727PC00

<160> 167

<170> PatentIn version 3.5

<210> 1

<211> 14

<212> PRT

<213> herpes simplex virus type 2

<400> 1

Thr Val Gly Pro Arg Gly Asn Ala Ser Asn Ala Ala Pro Ser
1 5 10

<210> 2

<211> 14

<212> PRT

<213> herpes simplex virus type 2

<400> 2

Ala Ser Ser Gln Ser Lys Pro Leu Ala Thr Gln Pro Pro Val
1 5 10

<210> 3

<211> 14

<212> PRT

<213> herpes simplex virus type 1

<400> 3

Asn Leu Thr Glu Tyr Ser Leu Ser Arg Val Asp Leu Gly Asp
1 5 10

<210> 4

<211> 14

eolf-othd-000002 (28).txt

<212> PRT

<213> herpes simplex virus type 1

<400> 4

Tyr Pro Asp Ala Val Tyr Leu His Arg Ile Asp Leu Gly Pro
1 5 10

<210> 5

<211> 14

<212> PRT

<213> herpes simplex virus type 1

<400> 5

Val Met Ser Val Leu Leu Val Asp Thr Asp Ala Thr Gln Gln
1 5 10

<210> 6

<211> 17

<212> PRT

<213> herpes simplex virus type 1

<400> 6

Val Met Ser Val Leu Leu Val Asp Thr Asp Ala Thr Gln Gln Gln Leu
1 5 10 15

Ala

<210> 7

<211> 17

<212> PRT

<213> herpes simplex virus type 1

<400> 7

Val Met Ser Val Leu Leu Val Asp Thr Asp Asn Thr Gln Gln Gln Ile
1 5 10 15

Ala

<210> 8
<211> 14
<212> PRT
<213> Enterovirus 71

<400> 8

Thr Asp Asp Gly Val Ser Ala Pro Ile Leu Pro Asn Phe His
1 5 10

<210> 9
<211> 22
<212> PRT
<213> Glycine max

<400> 9

Ser Ala Leu Leu Pro Val Gly Gln Pro Ser His Ala Pro Ser Val His
1 5 10 15

Leu Ala Ala Ala Thr Gln
20

<210> 10
<211> 10
<212> PRT
<213> herpes B virus

<400> 10

Arg Thr Pro Gly Asp Glu Pro Ala Pro Ala
1 5 10

<210> 11
<211> 14
<212> PRT
<213> herpes B virus

<400> 11

Arg Thr Pro Gly Asp Glu Pro Ala Pro Ala Val Ala Ala Gln
1 5 10

<210> 12
<211> 12
<212> PRT
<213> Canine adenovirus type 2

<400> 12

Phe Thr Ser Pro Leu His Lys Asn Glu Asn Thr Val
1 5 10

<210> 13
<211> 12
<212> PRT
<213> Canine adenovirus type 2

<400> 13

Phe Ala Tyr Pro Leu Val Lys Asn Asp Asn His Val
1 5 10

<210> 14
<211> 14
<212> PRT
<213> Canine adenovirus type 2

<400> 14

Ser Phe Thr Ser Pro Leu His Lys Asn Glu Asn Thr Val Ser
1 5 10

<210> 15
<211> 14
<212> PRT
<213> Homo sapiens

<400> 15

Phe Ser Lys Val Ser Ala Glu Thr Gln Ala Ser Pro Pro Glu
1 5 10

<210> 16
<211> 14

<212> PRT

<213> Clostridium botulinum

<400> 16

Glu Asp Asn Arg Gly Ile Asn Gln Lys Leu Ala Phe Asn Tyr
1 5 10

<210> 17

<211> 7

<212> PRT

<213> Tick-borne encephalitis virus

<400> 17

Gly Ala Tyr Val Ala Ala Asn
1 5

<210> 18

<211> 7

<212> PRT

<213> Tick-borne encephalitis virus

<400> 18

Ala Asp Thr Val Ala Ala Pro
1 5

<210> 19

<211> 14

<212> PRT

<213> Tick-borne encephalitis virus

<400> 19

Thr Gly Asp Tyr Val Ala Ala Asn Glu Thr His Ser Gly Arg
1 5 10

<210> 20

<211> 14

<212> PRT

<213> Measles virus

<400> 20

eolf-othd-000002 (28).txt

Ala Asp Ser Glu Ser Gly Gly His Ile Thr His Ser Gly Met
1 5 10

<210> 21
<211> 14
<212> PRT
<213> Measles virus

<400> 21

Ala Asp Ser Glu Ser Gly Glu His Ile Thr His Ser Gly Met
1 5 10

<210> 22
<211> 7
<212> PRT
<213> Armoracia rusticana

<400> 22

Glu Leu Phe Ser Ser Pro Asn
1 5

<210> 23
<211> 7
<212> PRT
<213> Armoracia rusticana

<400> 23

Val Leu Phe Ser Ser Pro Pro
1 5

<210> 24
<211> 14
<212> PRT
<213> Armoracia rusticana

<400> 24

Gly Leu Ile Gln Ser Asp Gln Glu Leu Phe Ser Ser Pro Asn
1 5 10

eolf-othd-000002 (28).txt

<210> 25
<211> 14
<212> PRT
<213> adeno-associated virus 1

<400> 25

Gly Gln Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro
1 5 10

<210> 26
<211> 14
<212> PRT
<213> adeno-associated virus 1

<400> 26

Gly Gln Thr Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro
1 5 10

<210> 27
<211> 14
<212> PRT
<213> Pseudorabies virus

<400> 27

Pro Ala His Leu Val Asn Val Ser Glu Gly Ala Asn Phe Thr
1 5 10

<210> 28
<211> 11
<212> PRT
<213> Pseudorabies virus

<400> 28

Leu Val Asn Val Ser Glu Gly Ala Asn Phe Thr
1 5 10

<210> 29
<211> 15
<212> PRT

eolf-othd-000002 (28).txt

<213> herpes simplex virus type 1

<400> 29

Ser Ala Leu Leu Glu Asp Pro Val Gly Thr Val Ala Pro Gln Ile
1 5 10 15

<210> 30

<211> 15

<212> PRT

<213> herpes simplex virus type 1

<400> 30

Ser Ala Leu Leu Glu Asp Pro Ala Gly Thr Val Ser Ser Gln Ile
1 5 10 15

<210> 31

<211> 14

<212> PRT

<213> Homo sapiens

<400> 31

Ser Ile Pro Gly Phe Pro Ala Glu Gly Ser Ile Pro Leu Pro
1 5 10

<210> 32

<211> 15

<212> PRT

<213> herpes simplex virus type 1

<400> 32

Ser Thr Leu Leu Pro Pro Glu Leu Ser Asp Thr Thr Asn Ala Thr
1 5 10 15

<210> 33

<211> 14

<212> PRT

<213> herpes simplex virus type 1

<400> 33

eolf-othd-000002 (28).txt

Ser Thr Leu Leu Pro Pro Glu Val Val Glu Thr Ala Asn Val
1 5 10

<210> 34
<211> 14
<212> PRT
<213> Canine adenovirus type 2

<400> 34

Glu Asp Glu Asn Gly Thr Leu Lys Val Thr Phe Pro Thr Pro
1 5 10

<210> 35
<211> 14
<212> PRT
<213> Canine adenovirus type 2

<400> 35

Val Asp Glu Asn Gly Thr Pro Lys Pro Ser Ser Leu Gly Arg
1 5 10

<210> 36
<211> 14
<212> PRT
<213> adeno-associated virus 1

<400> 36

Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly
1 5 10

<210> 37
<211> 14
<212> PRT
<213> adeno-associated virus 1

<400> 37

Gln Ser Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Val
1 5 10

eolf-othd-000002 (28).txt

<210> 38
<211> 14
<212> PRT
<213> adeno-associated virus 1

<400> 38

Gln Ser Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala
1 5 10

<210> 39
<211> 14
<212> PRT
<213> herpes simplex virus type 2

<400> 39

Asp Pro Gly Tyr Ala Glu Thr Pro Tyr Ala Ser Val Ser His
1 5 10

<210> 40
<211> 13
<212> PRT
<213> herpes simplex virus type 1

<400> 40

Pro Gly Gly Asp Val Pro Pro Ala Gly Pro Gly Glu Ile
1 5 10

<210> 41
<211> 13
<212> PRT
<213> herpes simplex virus type 1

<400> 41

Pro Gly Gly Glu Val Pro Pro Ala Gly Pro Gly Ala Ile
1 5 10

<210> 42
<211> 14
<212> PRT
<213> herpes simplex virus type 1

<400> 42

Leu Pro Gly Gly Glu Val Pro Pro Ala Gly Pro Gly Ala Ile
1 5 10

<210> 43

<211> 14

<212> PRT

<213> herpes simplex virus type 1

<400> 43

Gln Gln Ile Ala Ala Gly Pro Thr Glu Gly Ala Pro Ser Val
1 5 10

<210> 44

<211> 7

<212> PRT

<213> Clostridium botulinum

<400> 44

Leu Val Asp Thr Ser Gly Tyr
1 5

<210> 45

<211> 7

<212> PRT

<213> Clostridium botulinum

<400> 45

Tyr Val Asp Thr Ser Gly Tyr
1 5

<210> 46

<211> 7

<212> PRT

<213> Clostridium botulinum

<400> 46

Phe Ile Asp Ile Ser Gly Tyr

1 5

<210> 47
<211> 14
<212> PRT
<213> Clostridium botulinum

<400> 47

Asn Thr Leu Val Asp Thr Ser Gly Tyr Asn Ala Glu Val Ser
1 5 10

<210> 48
<211> 10
<212> PRT
<213> herpes simplex virus type 2

<400> 48

Gln Val Val Ala Val Glu Phe Asp Thr Phe
1 5 10

<210> 49
<211> 10
<212> PRT
<213> herpes simplex virus type 2

<400> 49

Gln Thr Val Ala Val Glu Phe Asp Thr Phe
1 5 10

<210> 50
<211> 14
<212> PRT
<213> herpes simplex virus type 2

<400> 50

Ser Gly Asp Gln Val Val Ala Val Glu Phe Asp Thr Phe Arg
1 5 10

<210> 51

<211> 42
<212> DNA
<213> herpes simplex virus type 2

<400> 51
accgtgggcc cccggggcaa cgccagcaac gccgccccca gc 42

<210> 52
<211> 42
<212> DNA
<213> herpes simplex virus type 2

<400> 52
gccagcagcc agagcaagcc cctggccacc cagccccccg tg 42

<210> 53
<211> 42
<212> DNA
<213> herpes simplex virus type 1

<400> 53
aacctgaccg agtacagcct gagccgggtg gacctgggcg ac 42

<210> 54
<211> 42
<212> DNA
<213> herpes simplex virus type 1

<400> 54
taccgacg ccgtgtacct gcaccggatc gacctgggcc cc 42

<210> 55
<211> 42
<212> DNA
<213> herpes simplex virus type 1

<400> 55
gtgatgagcg tgctgctggt ggacaccgac gccaccagc ag 42

<210> 56
<211> 51
<212> DNA
<213> herpes simplex virus type 1

eolf-othd-000002 (28).txt

<400> 56
gtgatgagcg tgctgctggt ggacaccgac gccacccagc agcagctggc c 51

<210> 57
<211> 51
<212> DNA
<213> herpes simplex virus type 1

<400> 57
gtgatgagcg tgctgctggt ggacaccgac aacacccagc agcagatcgc c 51

<210> 58
<211> 42
<212> DNA
<213> Enterovirus 71

<400> 58
accgacgacg gcgtgagcgc ccccatcctg cccaacttcc ac 42

<210> 59
<211> 66
<212> DNA
<213> Glycine max

<400> 59
agcgccctgc tgcccgtggg ccagcccagc cacgccccca gcgtgcacct ggccgcccgc 60

acccag 66

<210> 60
<211> 30
<212> DNA
<213> herpes B virus

<400> 60
cggacccccg gcgacgagcc cgcccccgcc 30

<210> 61
<211> 42
<212> DNA
<213> herpes B virus

eolf-othd-000002 (28).txt

<400> 61
cggacccccg gcgacgagcc cgcccccgcc gtggccgccc ag 42

<210> 62
<211> 36
<212> DNA
<213> Canine adenovirus type 2

<400> 62
ttcaccagcc ccctgcacaa gaacgagaac accgtg 36

<210> 63
<211> 36
<212> DNA
<213> Canine adenovirus type 2

<400> 63
ttcgctacc ccctggtgaa gaacgacaac cacgtg 36

<210> 64
<211> 42
<212> DNA
<213> Canine adenovirus type 2

<400> 64
agcttcacca gccccctgca caagaacgag aacaccgtga gc 42

<210> 65
<211> 42
<212> DNA
<213> Homo sapiens

<400> 65
ttcagcaagg tgagcgccga gaccagggcc agcccccccg ag 42

<210> 66
<211> 42
<212> DNA
<213> Clostridium botulinum

<400> 66
gaggacaacc ggggcatcaa ccagaagctg gccttcaact ac 42

eolf-othd-000002 (28).txt

<210> 67
<211> 21
<212> DNA
<213> Tick-borne encephalitis virus

<400> 67
ggcgcctacg tggccgcca c 21

<210> 68
<211> 21
<212> DNA
<213> Tick-borne encephalitis virus

<400> 68
gccgacaccg tggccgcccc c 21

<210> 69
<211> 42
<212> DNA
<213> Tick-borne encephalitis virus

<400> 69
accggcgact acgtggccgc caacgagacc cacagcggcc gg 42

<210> 70
<211> 42
<212> DNA
<213> Measles virus

<400> 70
gccgacagcg agagcggcgg ccacatcacc cacagcggca tg 42

<210> 71
<211> 44
<212> DNA
<213> Measles virus

<400> 71
gccgacagcg agagcggcga gcacatcacc cacagcggca tggc 44

<210> 72
<211> 21

<212> DNA
 <213> Armoracia rusticana

<400> 72
 gagctgttca gcagccca c 21

<210> 73
 <211> 23
 <212> DNA
 <213> Armoracia rusticana

<400> 73
 gtgctgttca gcagccccc cgc 23

<210> 74
 <211> 42
 <212> DNA
 <213> Armoracia rusticana

<400> 74
 ggcctgatcc agagcgacca ggagctgttc agcagccca ac 42

<210> 75
 <211> 42
 <212> DNA
 <213> adeno-associated virus 1

<400> 75
 ggccagaccg gcgacagcga gagcgtgccc gacccccagc cc 42

<210> 76
 <211> 42
 <212> DNA
 <213> adeno-associated virus 1

<400> 76
 ggccagaccg gcgacaccga gagcgtgccc gacccccagc cc 42

<210> 77
 <211> 42
 <212> DNA
 <213> Pseudorabies virus

eolf-othd-000002 (28).txt

<400> 77
cccgccacc tggatgaacgt gagcgagggc gcccaacttca cc 42

<210> 78
<211> 33
<212> DNA
<213> Pseudorabies virus

<400> 78
ctggtgaacg tgagcgaggg cgccaacttc acc 33

<210> 79
<211> 45
<212> DNA
<213> herpes simplex virus type 1

<400> 79
agcgccctgc tggaggacc cgtagggcacc gtggcccccc agatc 45

<210> 80
<211> 45
<212> DNA
<213> herpes simplex virus type 1

<400> 80
agcgccctgc tggaggacc cgccggcacc gtgagcagcc agatc 45

<210> 81
<211> 42
<212> DNA
<213> Homo sapiens

<400> 81
agcatccccg gcttccccgc cgagggcagc atccccctgc cc 42

<210> 82
<211> 45
<212> DNA
<213> herpes simplex virus type 1

<400> 82
agcacctgc tgccccccga gctgagcgac accaccaacg ccacc 45

<210> 83
<211> 42
<212> DNA
<213> herpes simplex virus type 1

<400> 83
agcaccctgc tgccccccga ggtggtggag accgccaacg tg 42

<210> 84
<211> 42
<212> DNA
<213> Canine adenovirus type 2

<400> 84
gaggacgaga acggcacct gaagtgacc ttccccaccc cc 42

<210> 85
<211> 42
<212> DNA
<213> Canine adenovirus type 2

<400> 85
gtggacgaga acggcacccc caagcccagc agcctgggcc gg 42

<210> 86
<211> 42
<212> DNA
<213> adeno-associated virus 1

<400> 86
agcagcaccg accccgccac cggcgacgtg cacgcatgg gc 42

<210> 87
<211> 42
<212> DNA
<213> adeno-associated virus 1

<400> 87
cagagcagca gcaccgaccc cgccaccggc gacgtgcacg tg 42

<210> 88
<211> 42

eolf-othd-000002 (28).txt

<212> DNA
<213> adeno-associated virus 1

<400> 88
cagagcagca gcaccgaccc cgccaccggc gacgtgcacg cc 42

<210> 89
<211> 42
<212> DNA
<213> herpes simplex virus type 2

<400> 89
gaccccggtc acgccgagac cccctacgcc agcgtgagcc ac 42

<210> 90
<211> 39
<212> DNA
<213> herpes simplex virus type 1

<400> 90
cccggcggcg acgtgcccc cgccggcccc ggcgagatc 39

<210> 91
<211> 39
<212> DNA
<213> herpes simplex virus type 1

<400> 91
cccggcggcg aggtgcccc cgccggcccc ggcgcatc 39

<210> 92
<211> 42
<212> DNA
<213> herpes simplex virus type 1

<400> 92
ctgcccggcg gcgaggtgcc ccccgccggc cccggcgcca tc 42

<210> 93
<211> 42
<212> DNA
<213> herpes simplex virus type 1

eolf-othd-000002 (28).txt

<400> 93
cagcagatcg ccgccggccc caccgagggc gccccagcg tg 42

<210> 94
<211> 21
<212> DNA
<213> Clostridium botulinum

<400> 94
ctggtggaca ccagcggcta c 21

<210> 95
<211> 21
<212> DNA
<213> Clostridium botulinum

<400> 95
tacgtggaca ccagcggcta c 21

<210> 96
<211> 21
<212> DNA
<213> Clostridium botulinum

<400> 96
ttcatcgaca tcagcggcta c 21

<210> 97
<211> 42
<212> DNA
<213> Clostridium botulinum

<400> 97
aacaccctgg tggacaccag cggctacaac gccgaggtga gc 42

<210> 98
<211> 30
<212> DNA
<213> herpes simplex virus type 2

<400> 98
caggtggagg ccgtggagtt cgacaccttc 30

eolf-othd-000002 (28).txt

<210> 99
<211> 46
<212> DNA
<213> herpes simplex virus type 2

<400> 99
ctgacaagac cacccagacc gtggccgtgg agttcgacac cttcgc 46

<210> 100
<211> 42
<212> DNA
<213> herpes simplex virus type 2

<400> 100
agcggcgacc aggtggtggc cgtggagttc gacaccttc gg 42

<210> 101
<211> 735
<212> PRT
<213> adeno-associated virus 2

<400> 101

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser
1 5 10 15

Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro
20 25 30

Lys Pro Ala Glu Arg His Lys Asp Asp Ser Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Arg Gln Leu Asp Ser Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95

eolf-othd-000002 (28).txt

Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Pro Val Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu His Ser Pro Val Glu Pro Asp Ser Ser Ser Gly Thr Gly
145 150 155 160

Lys Ala Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ala Asp Ser Val Pro Asp Pro Gln Pro Leu Gly Gln Pro Pro
180 185 190

Ala Ala Pro Ser Gly Leu Gly Thr Asn Thr Met Ala Thr Gly Ser Gly
195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Met Gly Asp Arg Val Ile
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Ala Ser Asn Asp Asn His Tyr
260 265 270

Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His
275 280 285

eolf-othd-000002 (28).txt

Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp
290 295 300

Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val
305 310 315 320

Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu
325 330 335

Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr
340 345 350

Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp
355 360 365

Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser
370 375 380

Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser
385 390 395 400

Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu
405 410 415

Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg
420 425 430

Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr
435 440 445

Asn Thr Pro Ser Gly Thr Thr Thr Gln Ser Arg Leu Gln Phe Ser Gln
450 455 460

Ala Gly Ala Ser Asp Ile Arg Asp Gln Ser Arg Asn Trp Leu Pro Gly
465 470 475 480

eolf-othd-000002 (28).txt

Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ser Ala Asp Asn Asn
485 490 495

Asn Ser Glu Tyr Ser Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly
500 505 510

Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Ser His Lys Asp
515 520 525

Asp Glu Glu Lys Phe Phe Pro Gln Ser Gly Val Leu Ile Phe Gly Lys
530 535 540

Gln Gly Ser Glu Lys Thr Asn Val Asp Ile Glu Lys Val Met Ile Thr
545 550 555 560

Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr
565 570 575

Gly Ser Val Ser Thr Asn Leu Gln Arg Gly Asn Arg Gln Ala Ala Thr
580 585 590

Ala Asp Val Asn Thr Gln Gly Val Leu Pro Gly Met Val Trp Gln Asp
595 600 605

Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620

Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys
625 630 635 640

His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn
645 650 655

Pro Ser Thr Thr Phe Ser Ala Ala Lys Phe Ala Ser Phe Ile Thr Gln
660 665 670

eolf-othd-000002 (28).txt

Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys
675 680 685

Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700

Asn Lys Ser Val Asn Val Asp Phe Thr Val Asp Thr Asn Gly Val Tyr
705 710 715 720

Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735

<210> 102
<211> 63
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> misc_feature
<222> (1)..(63)
<223> exemplary reference sequence

<400> 102
atgaagttat gggatgtcgt ggctgtctgc ctgggtttgc tccacaccgc gtctgccttc 60
ccg 63

<210> 103
<211> 21
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE
<222> (1)..(21)
<223> Exemplary reference sequence

<400> 103

Met Lys Leu Trp Asp Val Val Ala Val Cys Leu Val Leu Leu His Thr
1 5 10 15

Ala Ser Ala Phe Pro
 20

<210> 104
<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> MISC_FEATURE
<222> (1)..(14)
<223> exemplary reference sequence

<400> 104

Lys Leu Trp Asp Val Val Ala Val Cys Leu Val Leu Leu His
1 5 10

<210> 105
<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> MISC_FEATURE
<222> (1)..(14)
<223> exemplary reference sequence

<400> 105

Leu Trp Asp Val Val Ala Val Cys Leu Val Leu Leu His Thr
1 5 10

<210> 106

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> exemplary reference sequence

<400> 106

Trp Asp Val Val Ala Val Cys Leu Val Leu Leu His Thr Ala
1 5 10

<210> 107

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> exemplary reference sequence

<400> 107

Asp Val Val Ala Val Cys Leu Val Leu Leu His Thr Ala Ser
1 5 10

<210> 108

<211> 14

eolf-othd-000002 (28).txt

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> exemplary reference sequence

<400> 108

Val Val Ala Val Cys Leu Val Leu Leu His Thr Ala Ser Ala
1 5 10

<210> 109

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> exemplary reference sequence

<400> 109

Val Ala Val Cys Leu Val Leu Leu His Thr Ala Ser Ala Phe
1 5 10

<210> 110

<211> 24

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<400> 112
aaaggctcga gtgaagatgt 20

<210> 113
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> misc_feature
<222> (1)..(20)
<223> exemplary barcode

<400> 113
aagcccatgt gcacgcatat 20

<210> 114
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> misc_feature
<222> (1)..(20)
<223> exemplary barcode

<400> 114
aaggccggga gcatagcatc 20

<210> 115
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> misc_feature
<222> (1)..(20)
<223> exemplary barcode

<400> 115
aaggctgggc ttattggtgt 20

<210> 116
<211> 16
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> misc_feature
<222> (1)..(16)
<223> exemplary fragment

<400> 116
cggccctacg tgatgc 16

<210> 117
<211> 16
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> misc_feature
<222> (1)..(16)
<223> exemplary fragment

<400> 117
cggccctacc tggccc 16

<210> 118
<211> 16

<212> DNA
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> misc_feature
<222> (1)..(16)
<223> exemplary fragment

<400> 118
cggcccgtgg tgcccc

16

<210> 119
<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> misc_feature
<222> (1)..(17)
<223> exemplary fragment

<400> 119
cggcccgtgg tgagcac

17

<210> 120
<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> MISC_FEATURE
<222> (1)..(14)
<223> fragment of pUL22

<400> 120

Val Met Ser Val Leu Leu Val Asp Thr Asp Ala Thr Gln Gln
1 5 10

<210> 121

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> fragment of pUL22

<400> 121

Met Val Asp Thr Asp Ala Thr Gln Gln Gln Leu Ala Gln Gly
1 5 10

<210> 122

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> fragment of pUL22

<400> 122

Val Asp Thr Asp Ala Thr Gln Gln Gln Leu Ala Gln Gly Pro
1 5 10

<210> 123

<211> 22

eolf-othd-000002 (28).txt

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(22)

<223> fragment of pUL22

<400> 123

Pro Ala Gly Glu Val Met Ser Val Leu Leu Val Asp Thr Asp Asn Thr
1 5 10 15

Gln Gln Gln Ile Ala Ala
 20

<210> 124

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> fragment of pUL22

<400> 124

Ser Val Leu Leu Val Asp Thr Asp Asn Thr Gln Gln Gln Ile
1 5 10

<210> 125

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary/aligned sequence

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> fragment of pUL22

<400> 125

Val Asp Thr Asp Asn Thr Gln Gln Gln Ile Ala Ala Gly Pro
1 5 10

<210> 126

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> fragment of pUL22

<400> 126

Met Val Asp Thr Asp Asn Thr Gln Gln Gln Ile Ala Ala Gly
1 5 10

<210> 127

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> fragment of pUL22

<400> 127

Glu Val Met Ser Val Leu Leu Val Asp Thr Asp Ala Thr Gln
1 5 10

<210> 128

<211> 22

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(22)

<223> fragment of pUL22

<400> 128

Pro Ala Gly Glu Val Met Ser Val Leu Leu Val Asp Thr Asp Ala Thr
1 5 10 15

Gln Gln Gln Leu Ala Gln
20

<210> 129

<211> 22

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(22)

<223> fragment of pUL22

<400> 129

Glu Val Met Ser Val Leu Leu Val Asp Thr Asp Ala Thr Gln Gln Gln
1 5 10 15

Leu Ala Gln Gly Pro Val
20

<210> 130
<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> MISC_FEATURE
<222> (1)..(14)
<223> fragment of pUL22

<400> 130

Gln Gln Ile Ala Ala Gly Pro Thr Glu Gly Ala Pro Ser Val
1 5 10

<210> 131
<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> MISC_FEATURE
<222> (1)..(14)
<223> fragment of pUL22

<400> 131

Gln Ile Ala Ala Gly Pro Thr Glu Gly Ala Pro Ser Val Phe
1 5 10

<210> 132
<211> 14

eolf-othd-000002 (28).txt

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> fragment of pUL22

<400> 132

Glu Gly Ala Pro Ser Val Phe Ser Ser Asp Val Pro Ser Thr
1 5 10

<210> 133

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> fragment of pUL22

<400> 133

Thr Glu Gly Ala Pro Ser Val Phe Ser Ser Asp Val Pro Ser
1 5 10

<210> 134

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE
<222> (1)..(14)
<223> fragment of pUL22

<400> 134

Gln Gln Gln Ile Ala Ala Gly Pro Thr Glu Gly Ala Pro Ser
1 5 10

<210> 135
<211> 22
<212> PRT
<213> Homo sapiens

<400> 135

Thr Thr Ser Glu Pro Leu Pro Gln Asp Pro Val Lys Leu Pro Thr Thr
1 5 10 15

Ala Ala Ser Thr Pro Asp
20

<210> 136
<211> 14
<212> PRT
<213> Homo sapiens

<400> 136

Thr Thr Ser Glu Pro Leu Pro Gln Asp Pro Val Lys Leu Pro
1 5 10

<210> 137
<211> 22
<212> PRT
<213> Homo sapiens

<400> 137

Ser Gln Ser Leu Leu Lys Thr Thr Ser Glu Pro Leu Pro Gln Asp Pro
1 5 10 15

Val Lys Leu Pro Thr Thr

20

<210> 138
<211> 14
<212> PRT
<213> Homo sapiens

<400> 138

Thr Ser Glu Pro Leu Pro Gln Asp Pro Val Lys Leu Pro Thr
1 5 10

<210> 139
<211> 14
<212> PRT
<213> Homo sapiens

<400> 139

Gln Asp Pro Val Lys Leu Pro Thr Thr Ala Ala Ser Thr Pro
1 5 10

<210> 140
<211> 14
<212> PRT
<213> Theiler's encephalomyelitis virus

<400> 140

Asp Ala Ser Val Asp Phe Val Ala Glu Pro Val Lys Leu Pro
1 5 10

<210> 141
<211> 14
<212> PRT
<213> Theiler's encephalomyelitis virus

<400> 141

Ser Val Asp Phe Val Ala Glu Pro Val Lys Leu Pro Glu Asn
1 5 10

<210> 142

eolf-othd-000002 (28).txt

<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> MISC_FEATURE
<222> (1)..(14)
<223> conserved motif

<400> 142

Ser Ile Pro Gly Phe Pro Ala Glu Gly Ser Ile Pro Leu Pro
1 5 10

<210> 143
<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> MISC_FEATURE
<222> (1)..(14)
<223> conserved motif

<400> 143

Ile Pro Gly Phe Pro Ala Glu Gly Ser Ile Pro Leu Pro Ala
1 5 10

<210> 144
<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

eolf-othd-000002 (28).txt

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> conserved motif

<400> 144

Thr Thr Ser Ile Pro Gly Phe Pro Ala Glu Gly Ser Ile Pro
1 5 10

<210> 145

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> conserved motif

<400> 145

Ser Gly Glu Thr Thr Ser Ile Pro Gly Phe Pro Ala Glu Gly
1 5 10

<210> 146

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial/exemplary sequences

<220>

<221> MISC_FEATURE

<222> (1)..(14)

<223> conserved motif

<400> 146

Phe Ser Lys Val Ser Ala Glu Thr Gln Ala Ser Pro Pro Glu

1 5 10

<210> 147
<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> MISC_FEATURE
<222> (1)..(14)
<223> conserved motif

<400> 147

Ala Asp Phe Phe Ser Lys Val Ser Ala Glu Thr Gln Ala Ser
1 5 10

<210> 148
<211> 22
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> MISC_FEATURE
<222> (1)..(22)
<223> conserved motif

<400> 148

Ala Asp Phe Phe Ser Lys Val Ser Ala Glu Thr Gln Ala Ser Pro Pro
1 5 10 15

Glu Gly Pro Gly Thr Gly
20

<210> 149

eolf-othd-000002 (28).txt

<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial/exemplary sequences

<220>
<221> MISC_FEATURE
<222> (1)..(14)
<223> conserved motif

<400> 149

Glu Thr Gln Ala Ser Pro Pro Glu Gly Pro Gly Thr Gly Pro
1 5 10

<210> 150
<211> 14
<212> PRT
<213> Homo sapiens

<400> 150

Thr Gln Ala Ser Pro Pro Glu Gly Pro Gly Thr Gly Pro Ser
1 5 10

<210> 151
<211> 14
<212> PRT
<213> Homo sapiens

<400> 151

Gln Ala Ser Pro Pro Glu Gly Pro Gly Thr Gly Pro Ser Glu
1 5 10

<210> 152
<211> 14
<212> PRT
<213> Homo sapiens

<400> 152

eolf-othd-000002 (28).txt

Pro Glu Gly Pro Gly Thr Gly Pro Ser Glu Glu Gly His Glu
1 5 10

<210> 153
<211> 14
<212> PRT
<213> Homo sapiens

<400> 153

Glu Thr Gln Ala Ser Pro Pro Glu Gly Pro Gly Thr Gly Pro
1 5 10

<210> 154
<211> 14
<212> PRT
<213> Vesicular stomatitis virus

<400> 154

Ala Pro Lys Asn Pro Gly Thr Gly Pro Ala Phe Thr Ile Ile
1 5 10

<210> 155
<211> 14
<212> PRT
<213> Vesicular stomatitis virus

<400> 155

Ser Tyr Leu Ala Pro Lys Asn Pro Gly Thr Gly Pro Val Phe
1 5 10

<210> 156
<211> 14
<212> PRT
<213> Vesicular stomatitis virus

<400> 156

Tyr Leu Ala Pro Lys Asn Pro Gly Thr Gly Pro Val Phe Thr
1 5 10

eolf-othd-000002 (28).txt

<210> 157
<211> 14
<212> PRT
<213> Vesicular stomatitis virus

<400> 157

Leu Ser Tyr Leu Ala Pro Lys Asn Pro Gly Thr Gly Pro Ala
1 5 10

<210> 158
<211> 14
<212> PRT
<213> Human immunodeficiency virus

<400> 158

Cys Asn Asp Lys Asn Phe Asn Gly Thr Gly Pro Cys Lys Asn
1 5 10

<210> 159
<211> 14
<212> PRT
<213> Canine adenovirus type 2

<400> 159

Ser Phe Thr Ser Pro Leu His Lys Asn Glu Asn Thr Val Ser
1 5 10

<210> 160
<211> 14
<212> PRT
<213> Canine adenovirus type 2

<400> 160

Leu Ser Phe Thr Ser Pro Leu His Lys Asn Glu Asn Thr Val
1 5 10

<210> 161
<211> 14
<212> PRT
<213> Canine adenovirus type 2

<400> 161

Thr Phe Ala Tyr Pro Leu Val Lys Asn Asp Asn His Val Ala
1 5 10

<210> 162

<211> 14

<212> PRT

<213> Canine adenovirus type 2

<400> 162

Glu Asp Glu Asn Gly Thr Leu Lys Val Thr Phe Pro Thr Pro
1 5 10

<210> 163

<211> 14

<212> PRT

<213> Canine adenovirus type 2

<400> 163

Gly Leu Glu Asp Glu Asn Gly Thr Leu Lys Val Thr Phe Pro
1 5 10

<210> 164

<211> 14

<212> PRT

<213> Glycine max

<400> 164

Val Asp Glu Asn Gly Thr Pro Lys Pro Ser Ser Leu Gly Arg
1 5 10

<210> 165

<211> 14

<212> PRT

<213> Glycine max

<400> 165

Asn Lys Val Asp Glu Asn Gly Thr Pro Lys Pro Ser Ser Leu

1 5 10

<210> 166
<211> 14
<212> PRT
<213> Glycine max

<400> 166

Leu Asn Lys Val Asp Glu Asn Gly Thr Pro Lys Pro Ser Ser
1 5 10

<210> 167
<211> 14
<212> PRT
<213> Glycine max

<400> 167

Asp Glu Asn Gly Thr Pro Lys Pro Ser Ser Leu Gly Arg Ala
1 5 10